Page last updated: 2024-12-06

acarbose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Acarbose is a potent alpha-glucosidase inhibitor that is used to treat type 2 diabetes. It is synthesized through a multi-step process involving the glycosylation of a sugar-derived compound. Acarbose works by delaying the breakdown of complex carbohydrates in the intestines, resulting in a slower and more controlled rise in blood glucose levels. It is important because it can help improve glycemic control and reduce the risk of diabetes-related complications. Acarbose is studied extensively due to its potential for improving diabetes management and its unique mechanism of action, which differs from other antidiabetic drugs.'

chondramide B: a cytostatic cyclodepsipeptide; isolated from Chondromyces crocatus; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chondramide B : A chondramide that is chondramide A in which the hydrogen at position 2 of the indole moiety has been replaced by a chlorine. It is produced by strains of the myxobacterium, Chondromyces crocatus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID41774
CHEMBL ID404271
CHEMBL ID3734896
CHEBI ID2376
SCHEMBL ID5316305
MeSH IDM0070912
PubMed CID444254
CHEMBL ID1566
CHEBI ID94035
SCHEMBL ID16848
MeSH IDM0070912
PubMed CID73349255
CHEMBL ID2426320
CHEBI ID84381
MeSH IDM0070912

Synonyms (112)

Synonym
prandase
D00216
precose (tn)
acarbose (jan/usan/inn)
bay-g 5421
bay g 5421
CHEBI:2376 ,
glucobay
4,6-dideoxy-4-{[(1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-d-glucopyranosyl-(1->4)-alpha-d-glucopyranosyl-(1->4)-d-glucopyranose
precose
MLS001424056
56180-94-0
C06802
MLS000759506
smr000466376
NCGC00160515-01
SPECTRUM1505172
(3r,4r,5s,6r)-5-{[(2r,3r,4r,5s,6r)-5-{[(2r,3r,4s,5s,6r)-3,4-dihydroxy-6-methyl-5-{[(1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4-triol
bdbm23406
HMS2093I22
HMS2051F03
(3r,4r,5s,6r)-5-[(2r,3r,4r,5s,6r)-5-[(2r,3r,4s,5s,6r)-3,4-dihydroxy-6-methyl-5-[[(1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
STK801930
AKOS005622515
CHEMBL404271
pharmakon1600-01505172
nsc758915
HMS2236P06
CCG-100913
CCG-213345
AB00639959-06
NC00163
BBL030515
SCHEMBL5316305
MD-0230
MLS006011898
abamectin, antibiotic for culture media use only
Q-200574
AB00639959_08
mfcd00869592
SR-01000759407-6
SR-01000759407-5
SR-01000759407-4
sr-01000759407
SBI-0206777.P001
chembl3734896
bdbm50180587
prandase;
precose;
c25h43no18;
glucobay;
4,6-dideoxy-4-{[(1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-d-glucopyranosyl-(1->4)-alpha-d-glucopyranosyl-(1->4)-d-glucopyranose; precose (tn);
acarbose,(s)
acarbose; o-4,6-dideoxy-4-[[(1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-enyl]amino]-?-d-glucopyranosyl-(1?4)-o-?-d-glucopyranosyl-(1?4)-d-glucopyranose
BRD-A16444946-001-07-1
acarbose for identification
acarbose for peak identification
HMS3269L19
(2r,3r,4r,5s,6r)-5-((2r,3r,4r,5s,6r)-5-((2r,3r,4s,5s,6r)-3,4-dihydroxy-6-methyl-5-((1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-enylamino)-tetrahydro-2h-pyran-2-yloxy)-3,4-dihydroxy-6-(hydroxymethyl)-tetrahydro-2h-pyran-2-yloxy)-6-(hydroxyme
(3r,4r,5s,6r)-5-((2r,3r,4r,5s,6r)-5-((2r,3r,4s,5s,6r)-3,4-dihydroxy-6-methyl-5-((1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-enylamino)-tetrahydro-2h-pyran-2-yloxy)-3,4-dihydroxy-6-(hydroxymethyl)-tetrahydro-2h-pyran-2-yloxy)-6-(hydroxymethy
5-{5-[3,4-dihydroxy-6-methyl-5-(4,5,6-trihydroxy-3-hydroxymethyl-cyclohex-2-enylamino)-tetrahydro-pyran-2-yloxy]-3,4-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy}-6-hydroxymethyl-tetrahydro-pyran-2,3,4-triol
(2r,3r,4r,5r,6r)-5-((2r,3r,4r,5s,6r)-5-((2r,3r,4s,5s,6r)-3,4-dihydroxy-6-methyl-5-((1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-enylamino)-tetrahydro-2h-pyran-2-yloxy)-3,4-dihydroxy-6-(hydroxymethyl)-tetrahydro-2h-pyran-2-yloxy)-6-(hydroxyme
(2r,3r,4r,5s,6r)-5-((2r,3r,4r,5s,6r)-5-((2r,3r,4s,5s,6r)-3,4-dihydroxy-6-methyl-5-((1s,4s,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-enylamino)-tetrahydro-2h-pyran-2-yloxy)-3,4-dihydroxy-6-(hydroxymethyl)-tetrahydro-2h-pyran-2-yloxy)-6-(hydroxyme
bdbm50333465
glucor
bay-g-5421
1UKT
1AGM
beta-acarbose
qps
CHEMBL1566 ,
4-[5-[3,4-dihydroxy-6-methyl-5-[[2,3,4-trihydroxy-5-(hydroxymethyl)cyclohexyl]amino]tetrahydropyran-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-2,3,5,6-tetrahydroxy-hexanal;acarbose
A830944
tox21_111597
cas-56180-94-0
BCP9000224
BCPP000442
arcabose
ascarbose
S1271
gtpl6791
(2r,3r,4r,5s,6r)-5-[(2r,3r,4r,5s,6r)-5-[(2r,3r,4s,5s,6r)-3,4-dihydroxy-6-methyl-5-[[(1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
BRD-K44276885-001-01-7
CCG-220568
SCHEMBL16848
NCGC00160515-02
tox21_111597_1
AB01274765-01
o-4,6-dideoxy-4-[[(1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-?-d-glucopyranosyl-(1-4)-o-?-d-glucopyranosyl-(1-4)-d-glucose
d-glucose, o-4,6-dideoxy-4-[[(1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-.alpha.-d-glucopyranosyl-(1->4)-o-.alpha.-d-glucopyranosyl-(1->4)-
4,6-dideoxy-4-([1s]-[1,4,6/5]-4,5,6-trihydroxy-3-hydroxymethyl-2-yclohexenylamino)maltotriose
AKOS024457233
AB01274765_02
acarbose, >=95%
CHEBI:94035
acarbose, united states pharmacopeia (usp) reference standard
acarbose, pharmaceutical secondary standard; certified reference material
acarbose for peak identification, european pharmacopoeia (ep) reference standard
acarbose for identification, european pharmacopoeia (ep) reference standard
acarbose, european pharmacopoeia (ep) reference standard
HMS3713B18
Q338005
HMS3677P19
HMS3413P19
BRD-K44276885-001-07-4
(2r,3r,4r,5s,6r)-5-{[(2r,3r,4r,5s,6r)-5-{[(2r,3r,4s,5s,6r)-3,4-dihydroxy-6-methyl-5-{[(1s,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}oxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)oxane-2,3,4-triol
EN300-27025603
CHEMBL2426320
chebi:84381 ,
chondramide b
(3s,4s,7r,10s,13s,15e,17r,18r)-7-[(2-chloro-1h-indol-3-yl)methyl]-4-(4-hydroxyphenyl)-3-methoxy-8,10,13,15,17,18-hexamethyl-1-oxa-5,8,11-triazacyclooctadec-15-ene-2,6,9,12-tetrone
Q27157723

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
EC 3.2.1.20 (alpha-glucosidase) inhibitorAn EC 3.2.1.* (glycosidase) inhibitor that interferes with the action of alpha-glucosidase (EC 3.2.1.20).
EC 3.2.1.1 (alpha-amylase) inhibitorAn EC 3.2.1.* (glycosidase) inhibitor that interferes with the action of alpha-amylase (EC 3.2.1.1).
hypoglycemic agentA drug which lowers the blood glucose level.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
tetrasaccharide derivativeAn oligosaccharide derivative that is formally obtained from a tetrasaccharide.
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
amino cyclitolAny cyclitol having one or more alcoholic hydroxy groups replaced by substituted or unsubstituted amino groups.
chondramideAny of the 18-membered ring cyclodepsipeptides produced by strains of the myxobacterium, Chondromyces crocatus.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
indolesAny compound containing an indole skeleton.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency5.06380.036619.637650.1187AID1466; AID2100; AID2112; AID2242
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency4.46683.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency4.46683.548118.039535.4813AID1466
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency8.48520.000214.376460.0339AID720691
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.61780.000229.305416,493.5996AID743075; AID743077; AID743079
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency6.30960.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-amylaseAcarus siroIC50 (µMol)3.80003.80003.80003.8000AID1802682
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Maltase-glucoamylase, intestinalHomo sapiens (human)IC50 (µMol)423.93000.04003.46529.0000AID1370806; AID1378614; AID1381559; AID1416317; AID1504259; AID1509465; AID1509469; AID1546655; AID1608431; AID1609748; AID1684763; AID1873609
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Pancreatic alpha-amylaseSus scrofa (pig)IC50 (µMol)8.70861.35304.31088.9300AID1327604; AID1401021; AID1465050; AID1497070; AID1755850
Alpha-amylase 1A Homo sapiens (human)IC50 (µMol)0.99600.50004.02039.6400AID1798320
Lysosomal alpha-glucosidaseHomo sapiens (human)IC50 (µMol)533.17640.06002.28897.8000AID1370806; AID1378614; AID1381559; AID1416317; AID1459262; AID1504259; AID1509465; AID1509469; AID1546655; AID1608431; AID1609748
Sucrase-isomaltase, intestinalHomo sapiens (human)IC50 (µMol)504.75600.04902.72947.8000AID1370806; AID1378614; AID1381559; AID1416317; AID1504259; AID1509465; AID1509469; AID1546655; AID1608431; AID1609748
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)2.00000.00030.39075.4000AID1609748
Sucrase-isomaltase, intestinalRattus norvegicus (Norway rat)IC50 (µMol)20.20000.04001.848310.0000AID1427931
Alpha-glucosidase MAL32Saccharomyces cerevisiae S288CIC50 (µMol)328.87004.80007.10009.9000AID1802604; AID1802641; AID1802894
Oligo-1,6-glucosidase IMA1Saccharomyces cerevisiae S288CIC50 (µMol)415.97009.37009.37009.3700AID1328534; AID1801484; AID1801529; AID1801563; AID1801577; AID1801603; AID1802577; AID1802588; AID1802595
Lysosomal alpha-glucosidaseMus musculus (house mouse)IC50 (µMol)144.47004.00007.00009.0000AID1803327
Probable maltase-glucoamylase 2Homo sapiens (human)IC50 (µMol)504.75600.54004.02447.8000AID1370806; AID1378614; AID1381559; AID1416317; AID1504259; AID1509465; AID1509469; AID1546655; AID1608431; AID1609748
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Chain A, GLUCOAMYLASE-471Aspergillus awamoriKi0.00000.00000.00000.0000AID977610
Chain A, Cyclomaltodextrin glucanotransferaseBacillus sp. 1011IC50 (µMol)5,600.00005,600.00005,600.00005,600.0000AID977608
Maltase-glucoamylase, intestinalHomo sapiens (human)IC50 (µMol)906.00000.04003.46529.0000AID1196906
Pancreatic alpha-amylaseSus scrofa (pig)IC50 (µMol)35.50001.35304.31088.9300AID718833; AID724308
Alpha-glucosidase MAL62Saccharomyces cerevisiae (brewer's yeast)IC50 (µMol)390,210.00000.84001.42002.0000AID592240; AID729970
Alpha-amylase 1A Homo sapiens (human)IC50 (µMol)0.74800.50004.02039.6400AID1248385; AID404692
Lysosomal alpha-glucosidaseHomo sapiens (human)IC50 (µMol)148.92500.06002.28897.8000AID1235896; AID342799; AID342811; AID724304
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)IC50 (µMol)115.80000.00040.764912.5000AID1192378
Sucrase-isomaltase, intestinalRattus norvegicus (Norway rat)IC50 (µMol)79.75780.04001.848310.0000AID1070016; AID1172877; AID1181388; AID1250855; AID342795; AID342797; AID550397; AID578320; AID578321; AID593349; AID593353; AID594100; AID594101; AID641148; AID647238; AID711102; AID763817; AID768171
Oligo-1,6-glucosidase IMA1Saccharomyces cerevisiae S288CIC50 (µMol)167.65719.37009.37009.3700AID1064621; AID1192378; AID1239170; AID1800999; AID1801004; AID1801058; AID763819
Lysosomal alpha-glucosidaseMus musculus (house mouse)IC50 (µMol)100.00004.00007.00009.0000AID718832
Alpha-amylase Geobacillus stearothermophilusKi0.34000.34000.34000.3400AID590733
Lactase-phlorizin hydrolase Rattus norvegicus (Norway rat)IC50 (µMol)166.85000.12002.98674.4000AID738371
Lysosomal alpha-glucosidaseRattus norvegicus (Norway rat)IC50 (µMol)34.92070.08002.50619.8500AID1181386; AID1235896; AID1250854; AID342793; AID550393; AID578319; AID593351; AID594099; AID641146; AID647236; AID711104; AID738372; AID763818; AID768173
Lysosomal alpha-glucosidaseRattus norvegicus (Norway rat)Ki3.50000.00871.09573.5000AID590735
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pancreatic alpha-amylaseSus scrofa (pig)Kii5.87005.87005.87005.8700AID1465092
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (65)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
maltose catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
starch catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
dextrin catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
oligosaccharide metabolic processAlpha-amylase 1A Homo sapiens (human)
carbohydrate metabolic processAlpha-amylase 1A Homo sapiens (human)
maltose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
regulation of the force of heart contractionLysosomal alpha-glucosidaseHomo sapiens (human)
diaphragm contractionLysosomal alpha-glucosidaseHomo sapiens (human)
heart morphogenesisLysosomal alpha-glucosidaseHomo sapiens (human)
glycogen catabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
glucose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
lysosome organizationLysosomal alpha-glucosidaseHomo sapiens (human)
locomotory behaviorLysosomal alpha-glucosidaseHomo sapiens (human)
tissue developmentLysosomal alpha-glucosidaseHomo sapiens (human)
aorta developmentLysosomal alpha-glucosidaseHomo sapiens (human)
vacuolar sequesteringLysosomal alpha-glucosidaseHomo sapiens (human)
muscle cell cellular homeostasisLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling postureLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling balanceLysosomal alpha-glucosidaseHomo sapiens (human)
cardiac muscle contractionLysosomal alpha-glucosidaseHomo sapiens (human)
glycophagyLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose catabolic processSucrase-isomaltase, intestinalHomo sapiens (human)
polysaccharide digestionSucrase-isomaltase, intestinalHomo sapiens (human)
carbohydrate metabolic processProbable maltase-glucoamylase 2Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
maltose catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
starch catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
dextrin catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
oligosaccharide metabolic processAlpha-amylase 1A Homo sapiens (human)
carbohydrate metabolic processAlpha-amylase 1A Homo sapiens (human)
maltose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
regulation of the force of heart contractionLysosomal alpha-glucosidaseHomo sapiens (human)
diaphragm contractionLysosomal alpha-glucosidaseHomo sapiens (human)
heart morphogenesisLysosomal alpha-glucosidaseHomo sapiens (human)
glycogen catabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
glucose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
lysosome organizationLysosomal alpha-glucosidaseHomo sapiens (human)
locomotory behaviorLysosomal alpha-glucosidaseHomo sapiens (human)
tissue developmentLysosomal alpha-glucosidaseHomo sapiens (human)
aorta developmentLysosomal alpha-glucosidaseHomo sapiens (human)
vacuolar sequesteringLysosomal alpha-glucosidaseHomo sapiens (human)
muscle cell cellular homeostasisLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling postureLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling balanceLysosomal alpha-glucosidaseHomo sapiens (human)
cardiac muscle contractionLysosomal alpha-glucosidaseHomo sapiens (human)
glycophagyLysosomal alpha-glucosidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
catalytic activityMaltase-glucoamylase, intestinalHomo sapiens (human)
glucan 1,4-alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
protein bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
amylase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
carbohydrate bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
maltose alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
alpha-amylase activityAlpha-amylase 1A Homo sapiens (human)
calcium ion bindingAlpha-amylase 1A Homo sapiens (human)
chloride ion bindingAlpha-amylase 1A Homo sapiens (human)
alpha-1,4-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
carbohydrate bindingLysosomal alpha-glucosidaseHomo sapiens (human)
maltose alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
oligo-1,6-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
sucrose alpha-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
protein bindingSucrase-isomaltase, intestinalHomo sapiens (human)
carbohydrate bindingSucrase-isomaltase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
glucan 1,4-alpha-glucosidase activityProbable maltase-glucoamylase 2Homo sapiens (human)
carbohydrate bindingProbable maltase-glucoamylase 2Homo sapiens (human)
alpha-1,4-glucosidase activityProbable maltase-glucoamylase 2Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
catalytic activityMaltase-glucoamylase, intestinalHomo sapiens (human)
glucan 1,4-alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
protein bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
amylase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
carbohydrate bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
maltose alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-amylase activityAlpha-amylase 1A Homo sapiens (human)
calcium ion bindingAlpha-amylase 1A Homo sapiens (human)
chloride ion bindingAlpha-amylase 1A Homo sapiens (human)
alpha-1,4-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
carbohydrate bindingLysosomal alpha-glucosidaseHomo sapiens (human)
maltose alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
apical plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular exosomeMaltase-glucoamylase, intestinalHomo sapiens (human)
tertiary granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
ficolin-1-rich granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceAlpha-amylase 1A Homo sapiens (human)
extracellular exosomeAlpha-amylase 1A Homo sapiens (human)
extracellular spaceAlpha-amylase 1A Homo sapiens (human)
lysosomeLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal membraneLysosomal alpha-glucosidaseHomo sapiens (human)
plasma membraneLysosomal alpha-glucosidaseHomo sapiens (human)
membraneLysosomal alpha-glucosidaseHomo sapiens (human)
azurophil granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal lumenLysosomal alpha-glucosidaseHomo sapiens (human)
intracellular membrane-bounded organelleLysosomal alpha-glucosidaseHomo sapiens (human)
extracellular exosomeLysosomal alpha-glucosidaseHomo sapiens (human)
tertiary granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
ficolin-1-rich granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
autolysosome lumenLysosomal alpha-glucosidaseHomo sapiens (human)
Golgi apparatusSucrase-isomaltase, intestinalHomo sapiens (human)
plasma membraneSucrase-isomaltase, intestinalHomo sapiens (human)
brush borderSucrase-isomaltase, intestinalHomo sapiens (human)
apical plasma membraneSucrase-isomaltase, intestinalHomo sapiens (human)
extracellular exosomeSucrase-isomaltase, intestinalHomo sapiens (human)
membraneProbable maltase-glucoamylase 2Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
apical plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular exosomeMaltase-glucoamylase, intestinalHomo sapiens (human)
tertiary granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
ficolin-1-rich granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular spaceAlpha-amylase 1A Homo sapiens (human)
extracellular exosomeAlpha-amylase 1A Homo sapiens (human)
extracellular spaceAlpha-amylase 1A Homo sapiens (human)
lysosomeLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal membraneLysosomal alpha-glucosidaseHomo sapiens (human)
plasma membraneLysosomal alpha-glucosidaseHomo sapiens (human)
membraneLysosomal alpha-glucosidaseHomo sapiens (human)
azurophil granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal lumenLysosomal alpha-glucosidaseHomo sapiens (human)
intracellular membrane-bounded organelleLysosomal alpha-glucosidaseHomo sapiens (human)
extracellular exosomeLysosomal alpha-glucosidaseHomo sapiens (human)
tertiary granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
ficolin-1-rich granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
autolysosome lumenLysosomal alpha-glucosidaseHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (629)

Assay IDTitleYearJournalArticle
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1446637Inhibition of alpha-amylase (unknown origin) using starch as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by dinitrosalicylic acid color reagent based assay2017Journal of natural products, 02-24, Volume: 80, Issue:2
Antibacterial and Hypoglycemic Diterpenoids from Salvia chamaedryoides.
AID1566622Inhibition of baker's yeast alpha-glucosidase using p-nitrophenyl alpha-D-glucopyranoside as substrate measured after 30 mins by spectrophotometry analysis2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1378614Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl glycoside as substrate treated 20 mins post substrate addition measured for 1 min by spectrophotometric analysis2017Journal of natural products, 08-25, Volume: 80, Issue:8
Bioactive Azaphilone Derivatives from the Fungus Talaromyces aculeatus.
AID1369348Antiobesity activity in C57BL/6J DIO mouse assessed as reduction in cumulative food intake at 3 mg/kg administered daily via oral gavage for 5 weeks2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo.
AID1576412Inhibition of starch utilization system in Bacteroides dorei JRO3 assessed as increase in doubling time at 10 uM in presence of pullulan by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1872865Inhibition of alpha-glucosidase (unknown origin) using PNP glycoside as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by spectrophotometric analysis2022European journal of medicinal chemistry, May-05, Volume: 235Recent results from non-basic glycosidase inhibitors: How structural diversity can inform general strategies for improving inhibition potency.
AID1873610Inhibition of alpha-glucosidase (unknown origin) using PNPG as substrate at 5 to 45 uM preincubated for 15 mins followed by substrate addition and measured after 10 mins by microplate reader analysis2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors.
AID1591956Inhibition of Saccharomyces cerevisiae alpha-glucosidase using PNP-G as substrate incubated for 20 mins followed by substrate addition2019Journal of natural products, 08-23, Volume: 82, Issue:8
Bioactive Polyketide Derivatives from the Mangrove-Derived Fungus
AID1447206Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 1.25 mg/mL preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID1446636Inhibition of alpha-glucosidase (unknown origin) using 4-nitrophenyl alpha-D-glucopyranoside as substrate after 10 mins2017Journal of natural products, 02-24, Volume: 80, Issue:2
Antibacterial and Hypoglycemic Diterpenoids from Salvia chamaedryoides.
AID1401021Inhibition of porcine pancreatic alpha-amylase using starch as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by dinitrosalicylic acid color reagent based assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Synthesis of piperazine sulfonamide analogs as diabetic-II inhibitors and their molecular docking study.
AID1370495Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitro-phenyl-alpha-D-glucopyranoside as substrate preincubated with enzyme followed by substrate addition measured after 10 mins for every 2.5 to 5 mins2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Chemical constituents from Taraxacum officinale and their α-glucosidase inhibitory activities.
AID1497885Inhibition of almond beta-glucosidase at 25 uM using p-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1667360Inhibition of alpha-glucosidase (unknown origin) using p-NPG as substrate by spectrophotometric analysis2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Tetra-aryl cyclobutane and stilbenes from the rhizomes of Rheum undulatum and their α-glucosidase inhibitory activity: Biological evaluation, kinetic analysis, and molecular docking simulation.
AID1316801Inhibition of alpha-glucosidase (unknown origin) assessed as reduction in PNP release using PNPG as substrate preincubated for 10 mins followed by substrate addition measured after 40 mins by spectrophotometric method2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Gabosines P and Q, new carbasugars from Streptomyces sp. and their α-glucosidase inhibitory activity.
AID1465076Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 620 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 3.7 uM betulinic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1662170Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenylglucopyranoside as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Anti-diabetic drugs recent approaches and advancements.
AID1416004Inhibition of human alpha-amylase at 100 ug/ml using starch as substrate preincubated for 30 mins by 3,5-dinitrosalicylic acid color reagent based assay relative to control2017MedChemComm, Jul-01, Volume: 8, Issue:7
Synthesis of novel inhibitors of α-amylase based on the thiazolidine-4-one skeleton containing a pyrazole moiety and their configurational studies.
AID1609747Inhibition of alpha-amylase (unknown origin) using starch as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by dinitrosalicylic acid reagent based assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis of benzotriazoles derivatives and their dual potential as α-amylase and α-glucosidase inhibitors in vitro: Structure-activity relationship, molecular docking, and kinetic studies.
AID1688687Inhibition of Saccharomyces cerevisiae alpha-glucosidase using PNPG as substrate incubated for 10 mins by spectrophotometric method2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID1504259Inhibition of alpha-glucosidase (unknown origin) using p-NPG as substrate pretreated for 10 mins followed by substrate addition measured after 5 mins2017Journal of natural products, 11-22, Volume: 80, Issue:11
Bioactive Asarone-Derived Phenylpropanoids from the Rhizome of Acorus tatarinowii Schott.
AID1684763Inhibition of human intestinal maltase using maltose as substrate incubated for 30 mins and immediately heated for 2 mins by glucose oxidase method2021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Elongation of the side chain by linear alkyl groups increases the potency of salacinol, a potent α-glucosidase inhibitor from the Ayurvedic traditional medicine "Salacia," against human intestinal maltase.
AID1465073Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 1240 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 8.6 uM corosolic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1514081In vivo inhibition of intestinal maltase-glucoamylase in Wistar rat assessed as reduction in postprandial hyperglycemia at 5 mg/kg, po pretreated for 30 mins followed by maltose challenge and measured after 30 to 120 mins by OMTT2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Synthesis, in vitro and in vivo evaluation of 2-aryl-4H-chromene and 3-aryl-1H-benzo[f]chromene derivatives as novel α-glucosidase inhibitors.
AID1576422Effect on growth of Bacteroides dorei JRO4 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of glucose by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1757080Competitive inhibition of Saccharomyces cerevisiae alpha-glucosidase using alpha-PNPG as substrate incubated for 30 mins by Lineweaver-Burk plot analysis2021European journal of medicinal chemistry, Apr-15, Volume: 2162,5-Disubstituted furan derivatives containing 1,3,4-thiadiazole moiety as potent α-glucosidase and E. coli β-glucuronidase inhibitors.
AID1695061Inhibition of porcine pancreatic alpha-amylase assessed as reduction in conversion of starch to glucose using starch as substrate incubated for 15 mins by starch-iodine method2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Arylsulfonyl histamine derivatives as powerful and selective α-glucosidase inhibitors.
AID1663505Hypoglycemic activity in starch administered mouse assessed as reduction in post prandial blood glucose level at 25 mg/kg, po measured after 30 mins relative to control2020Bioorganic & medicinal chemistry letters, 08-01, Volume: 30, Issue:15
3,4-Dihydroxyphenethyl nitrate with nitric oxide releasing, antioxidant, hypoglycemic and hypolipidemic effects.
AID1608431Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl alpha-d-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by spectrophotometric analysis2019European journal of medicinal chemistry, Oct-15, Volume: 180Role of sulphur-heterocycles in medicinal chemistry: An update.
AID1491048Inhibition of recombinant Ruminococcus obeum ATCC 29174 alpha-glucosidase expressed in Escherichia coli BL21(DE3) using p-nitrophenyl-alpha-D-glucopyranoside as substrate pretreated for 10 mins followed by substrate addition measured after 3 hrs2017Journal of natural products, 05-26, Volume: 80, Issue:5
α-Glucosidase Inhibitors from Salvia circinata.
AID1755850Inhibition of porcine pancreatic alpha-amylase using 1% starch as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by absorbance method2021European journal of medicinal chemistry, Jan-15, Volume: 210Metronidazole-conjugates: A comprehensive review of recent developments towards synthesis and medicinal perspective.
AID1331253Inhibition of Saccharomyces cerevisiae alpha-glucosidase using PNPG as substrate at 200 uM preincubated for 10 mins followed by substrate addition measured after 10 mins2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
New polyhydroxytriterpenoid derivatives from fruits of Terminalia chebula Retz. and their α-glucosidase and α-amylase inhibitory activity.
AID1663499Inhibition of rat intestinal maltase2020Bioorganic & medicinal chemistry letters, 08-01, Volume: 30, Issue:15
3,4-Dihydroxyphenethyl nitrate with nitric oxide releasing, antioxidant, hypoglycemic and hypolipidemic effects.
AID1491050Antihyperglycemic activity in ICR mouse assessed as reduction in postprandial blood glucose levels at 5 mg/kg, ig pretreated for 30 mins followed by oral sucrose challenge measured at 30 mins interval for 120 mins by OSTT2017Journal of natural products, 05-26, Volume: 80, Issue:5
α-Glucosidase Inhibitors from Salvia circinata.
AID1662166Inhibition of alpha-glucosidase (unknown origin)2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Anti-diabetic drugs recent approaches and advancements.
AID1576406Inhibition of starch utilization system in Bacteroides dorei JRO3 assessed as bacterial growth at 1 uM after 13.5 hrs in presence of pullulan by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1465065Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 1240 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 17.8 uM oleanolic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1465054Synergistic inhibition of porcine pancreatic alpha-amylase assessed as combination index at 2.6 uM preincubated for 15 mins followed by starch addition measured after 10 mins in presence of 47.1 uM oleanolic acid by dinitrosalicylic acid reagent based ass2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1628030Inhibition of rat small intestinal sucrase using sucrose as substrate assessed as amount of liberated glucose at 0.02 mM after 30 mins by glucose oxidase method2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Rat intestinal sucrase inhibited by minor constituents from the leaves and twigs of Archidendron clypearia (Jack.) Nielsen.
AID1697252Inhibition of alpha-glucosidase in rat everted intestinal sleeves assessed as reduction in blood glucose AUC (0-90) outside of the intestinal sleeves at 0.5 mM2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Exploring efficacy of natural-derived acetylphenol scaffold inhibitors for α-glucosidase: Synthesis, in vitro and in vivo biochemical studies.
AID1657617Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 100 uM using p-nitrophenyl alpha-Dglucopyranoside as substrate preincubated for 15 mins followed by substrate addition and measured after 20 mins relative to control2020Journal of natural products, 05-22, Volume: 83, Issue:5
Phenylpropanoid-Conjugated Triterpenoids from the Leaves of
AID1865587Inhibition of alpha glucosidase (unknown origin)2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
Fragment-Based Dynamic Combinatorial Chemistry for Identification of Selective α-Glucosidase Inhibitors.
AID1891151Inhibition of alpha-glycosidase (unknown origin) using p-NPG as substrate incubated for 10 mins2022Bioorganic & medicinal chemistry letters, 06-01, Volume: 65Polyphenolic compounds: Synthesis, assessment of antimicrobial effect and enzymes inhibition against important medicinal enzymes with computational details.
AID1609748Inhibition of alpha-glucosidase (unknown origin)2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis of benzotriazoles derivatives and their dual potential as α-amylase and α-glucosidase inhibitors in vitro: Structure-activity relationship, molecular docking, and kinetic studies.
AID1576413Inhibition of starch utilization system in Bacteroides dorei JRO3 assessed as increase in doubling time at 0.1 to 10 uM in presence of potato by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1888482Anti-hyperglycemic activity in Wistar rat assessed as reduction in plasma glucose AUC (0 to 120 mins) at 5 mg/kg, po followed by maltose load by oral maltose tolerance test2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Towards multi-target antidiabetic agents: In vitro and in vivo evaluation of 3,5-disubstituted indolin-2-one derivatives as novel α-glucosidase inhibitors.
AID1398126Inhibition of almond beta-glucosidase at 80 uM using PNPG as substrate after 3 mins by UV-vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1576405Inhibition of starch utilization system in Bacteroides dorei JRO3 assessed as bacterial growth at 5 uM after 14 hrs in presence of potato starch by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1668165Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl alpha-D-glucoside as substrate preincubated for 10 mins followed by substrate addition measured after 20 mins by colorimetric assay2020Bioorganic & medicinal chemistry, 05-15, Volume: 28, Issue:10
α-Glucosidase inhibitory and nitric oxide production inhibitory activities of alkaloids isolated from a twig extract of Polyalthia cinnamomea.
AID1465062Synergistic inhibition of porcine pancreatic alpha-amylase assessed as combination index at 5.3 uM preincubated for 15 mins followed by starch addition measured after 10 mins in presence of 22.6 uM urosolic acid by dinitrosalicylic acid reagent based assa2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1892597Antidiabetic activity against STZ-induced diabetic Sprague-Dawley rat model assessed as reduction in fasting blood glucose level at 80 mg/kg, IG administered once daily for 28 days2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Novel Hydroxychalcone-Based Dual Inhibitors of Aldose Reductase and α-Glucosidase as Potential Therapeutic Agents against Diabetes Mellitus and Its Complications.
AID1427931Inhibition of sucrase in rat small intestinal mucosa assessed as reduction in glucose production using sucrose as substrate measured after 40 mins by glucose oxidase assay2017European journal of medicinal chemistry, Feb-15, Volume: 127A novel class of α-glucosidase and HMG-CoA reductase inhibitors from Ganoderma leucocontextum and the anti-diabetic properties of ganomycin I in KK-A
AID1369327Inhibition of rat small intestinal mucosal alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate after 40 mins by colorimetric method2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo.
AID1576415Effect on growth of Bacteroides dorei JRO2 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of maltose by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1427932Inhibition of maltase in rat small intestinal mucosa assessed as reduction in glucose production using maltose as substrate measured after 40 mins by glucose oxidase assay2017European journal of medicinal chemistry, Feb-15, Volume: 127A novel class of α-glucosidase and HMG-CoA reductase inhibitors from Ganoderma leucocontextum and the anti-diabetic properties of ganomycin I in KK-A
AID1497883Inhibition of almond beta-glucosidase at 10 uM using p-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1546788Inhibition of Saccharomyces cerevisiae alpha-glucosidase assessed as decrease in release of p-nitrophenol using pNPG as substrate preincubated for 15 min followed by substrate addition and measured after 5 mins by spectrophotometric method2020Journal of natural products, 01-24, Volume: 83, Issue:1
α-Glucosidase Inhibitory Isomeric Corniculatolides from the Stems of the Indian Mangrove Plant,
AID1663938Inhibition of alpha-glucosidase (unknown origin)2020Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14
Synthesis of tetracyclic oxindoles and evaluation of their α-glucosidase inhibitory and glucose consumption-promoting activity.
AID1591998Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 669.57 uM incubated for 30 mins before pNPG substrate addition and measured after 10 mins by spectrophotometry relative to untreated control2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
α-Glucosidase inhibition activity and in silico study of 2-(benzo[d][1,3]dioxol-5-yl)-4H-chromen-4-one, a synthetic derivative of flavone.
AID1498910Inhibition of Saccharomyces cerevisiae alpha-glucosidase using pNPG as substrate preincubated for 15 mins followed by substrate addition measured for 30 mins by spectrophotometric method2018Bioorganic & medicinal chemistry, 07-30, Volume: 26, Issue:13
Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.
AID1576426Inhibition of starch utilization system in Bacteroides dorei JRO3 assessed as increase in lag time at 5 uM up to 48 hrs in presence of pullulan by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1465075Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 4958 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 34.3 uM corosolic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1576410Inhibition of starch utilization system in Bacteroides dorei JRO3 assessed as reduction in bacterial growth at 0.1 uM after 13.5 hrs in presence of pullulan by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1497886Inhibition of almond beta-glucosidase at 45 uM using p-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1398122Inhibition of almond beta-glucosidase at 10 uM using PNPG as substrate after 3 mins by UV-vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1398119Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 80 uM using PNPG as substrate after 3 mins by UV-vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1576424Inhibition of starch utilizing system in Bacteroides dorei JRO4 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of pullulan by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1632879Inhibition of baker's yeast alpha-glucosidase using p-nitrophenyl alpha-D-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured for 20 mins by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies and synthesis of novel bisbenzimidazole derivatives as inhibitors of α-glucosidase.
AID1459262Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by spectrophotometric method2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis, in vitro evaluation and molecular docking studies of novel triazine-triazole derivatives as potential α-glucosidase inhibitors.
AID1370806Inhibition of alpha-glucosidase (unknown origin) using p-nitro-phenyl-alpha-D-glucopyranoside as substrate preincubated for 5 mins with substrate followed by enzyme addition measure after 15 mins by spectrophotometric method2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
New butenolide derivatives from the marine sponge-derived fungus Aspergillus terreus.
AID1475099Inhibition of alpha-glucosidase (unknown origin)2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Structure-related protein tyrosine phosphatase 1B inhibition by naringenin derivatives.
AID1437653Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate after 30 mins2017Journal of natural products, 01-27, Volume: 80, Issue:1
α-Glucosidase Inhibitors from Malbranchea flavorosea.
AID1416005Inhibition of human alpha-amylase at 200 ug/ml using starch as substrate preincubated for 30 mins by 3,5-dinitrosalicylic acid color reagent based assay relative to control2017MedChemComm, Jul-01, Volume: 8, Issue:7
Synthesis of novel inhibitors of α-amylase based on the thiazolidine-4-one skeleton containing a pyrazole moiety and their configurational studies.
AID1398123Inhibition of almond beta-glucosidase at 20 uM using PNPG as substrate after 3 mins by UV-vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1497889Inhibition of almond beta-glucosidase at 180 uM using p-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1377003Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate after 30 mins2017Journal of natural products, 06-23, Volume: 80, Issue:6
Lignans from the Roots of Taxus wallichiana and Their α-Glucosidase Inhibitory Activities.
AID1509464Inhibition of yeast alpha-glucosidase using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins2019European journal of medicinal chemistry, Aug-15, Volume: 176Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview.
AID1662494Inhibition of alpha-amylase (unknown origin) using starch as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by dinitrosalicylic acid reagent based assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Syntheses, in vitro α-amylase and α-glucosidase dual inhibitory activities of 4-amino-1,2,4-triazole derivatives their molecular docking and kinetic studies.
AID1437657Antihyperglycemic activity in nicotinamide/streptozotocin-induced ICR mouse hyperglycemic model assessed as decrease in postprandial blood glucose levels at 5 mg/kg administered 30 mins followed by oral sucrose challenge measured after 30 to 120 mins by O2017Journal of natural products, 01-27, Volume: 80, Issue:1
α-Glucosidase Inhibitors from Malbranchea flavorosea.
AID1465053Synergistic inhibition of porcine pancreatic alpha-amylase assessed as combination index at 1.3 uM preincubated for 15 mins followed by starch addition measured after 10 mins in presence of 23.5 uM oleanolic acid by dinitrosalicylic acid reagent based ass2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1509465Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins2019European journal of medicinal chemistry, Aug-15, Volume: 176Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview.
AID1576409Inhibition of starch utilization system in Bacteroides dorei JRO3 assessed as bacterial growth at 0.5 uM after 14 hrs in presence of potato starch by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1624293Inhibition of baker's yeast alpha-glucosidase using phenol-alphaD-glycopyranoside as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins2019European journal of medicinal chemistry, Feb-15, Volume: 164Synthesis and biological evaluation of novel oleanolic acid analogues as potential α-glucosidase inhibitors.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1773664Inhibition of Saccharomyces cerevisiae alpha-glucosidase using pNPG as substrate preincubated for 10 mins followed by substrate addition and measured for 35 mins by microplate photometric method2021Journal of natural products, 09-24, Volume: 84, Issue:9
Dual High-Resolution α-Glucosidase and PTP1B Inhibition Profiling Combined with HPLC-PDA-HRMS-SPE-NMR Analysis for the Identification of Potentially Antidiabetic Chromene Meroterpenoids from
AID1383590Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 15 to 20 mins followed by substrate addition measured after 45 to 60 mins by spectrophotometric analysis2018European journal of medicinal chemistry, Apr-25, Volume: 150Synthesis, molecular modeling and evaluation of α-glucosidase inhibition activity of 3,4-dihydroxy piperidines.
AID1398116Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 20 uM using PNPG as substrate after 3 mins by UV-vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1688018Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitophenyl alpha 7-D-glucoside incubated for 45 mins2020European journal of medicinal chemistry, Feb-15, Volume: 188Synthesis and biological evaluation of some novel 1,2,3-triazole hybrids of myrrhanone B isolated from Commiphora mukul gum resin: Identification of potent antiproliferative leads active against prostate cancer cells (PC-3).
AID1497890Inhibition of almond beta-glucosidase using p-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1368890Inhibition of Saccharomyces cerevisiae alpha-glucosidase pre-incubated for 15 mins before p-nitrophenyl alpha-D-glucopyranoside substrate addition and measured after 30 mins by spectrophotometry2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
Synthesis, in vitro α-glucosidase inhibitory activity and docking studies of novel chromone-isatin derivatives.
AID1625133Inhibition of yeast alpha-glucosidase using pNP-alpha-G as substrate measured after 30 mins2019Journal of natural products, 03-22, Volume: 82, Issue:3
Synthesis of Rosmarinic Acid Amides as Antioxidative and Hypoglycemic Agents.
AID1497887Inhibition of almond beta-glucosidase at 80 uM using p-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1757078Inhibition of Saccharomyces cerevisiae alpha-glucosidase assessed as reduction in PNP formation at 10 uM using alpha-PNPG as substrate incubated for 30 mins relative to control2021European journal of medicinal chemistry, Apr-15, Volume: 2162,5-Disubstituted furan derivatives containing 1,3,4-thiadiazole moiety as potent α-glucosidase and E. coli β-glucuronidase inhibitors.
AID1684770Inhibition of rat intestinal maltase2021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Elongation of the side chain by linear alkyl groups increases the potency of salacinol, a potent α-glucosidase inhibitor from the Ayurvedic traditional medicine "Salacia," against human intestinal maltase.
AID1624301Hypoglycemic activity in streptozocin-induced diabetic Kunming mouse assessed as blood glucose level at 50 mg/kg, po administered once daily for 18 days measured on day 6 post dose (Rvb = 22.31 +/- 1.05 mM)2019European journal of medicinal chemistry, Feb-15, Volume: 164Synthesis and biological evaluation of novel oleanolic acid analogues as potential α-glucosidase inhibitors.
AID1465061Synergistic inhibition of porcine pancreatic alpha-amylase assessed as combination index at 2.6 uM preincubated for 15 mins followed by starch addition measured after 10 mins in presence of 11.3 uM urosolic acid by dinitrosalicylic acid reagent based assa2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1398115Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 10 uM using PNPG as substrate after 3 mins by UV-vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1465081Inhibition of porcine pancreatic alpha-amylase assessed as Km for substrate using starch as substrate at 5.3 uM by Michaelis-Menten plot analysis (Rvb = 2.48 +/- 0.24 mg/ml)2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1422323Inhibition of alpha-amylase (unknown origin) using starch as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by dinitrosalicylic acid color reagent based assay2018European journal of medicinal chemistry, Nov-05, Volume: 1592'-Aryl and 4'-arylidene substituted pyrazolones: As potential α-amylase inhibitors.
AID1497875Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 10 uM using 4-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1465087Inhibition of porcine pancreatic alpha-amylase assessed as Vmax for substrate using starch as substrate at 5.3 uM by Michaelis-Menten plot analysis (Rvb = 28.6 +/- 1.8 microg/ml/min)2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1576427Inhibition of starch utilization system in Bacteroides dorei JRO3 assessed as increase in lag time at 0.1 to 10 uM up to 48 hrs in presence of potato starch by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1398118Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 60 uM using PNPG as substrate after 3 mins by UV-vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1398128Inhibition of almond beta-glucosidase using PNPG as substrate after 3 mins by UV-vis spectrophotometric method2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1766977Inhibition of Type-1 alpha glucosidase (unknown origin)2021Journal of natural products, 05-28, Volume: 84, Issue:5
α-Glucosidase Inhibitors from
AID1570214Inhibition of yeast alpha-glucosidase using p-nitrophenyl glucopyranoside as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins2019European journal of medicinal chemistry, 10-15, Volume: 180An insight into the medicinal perspective of synthetic analogs of indole: A review.
AID1465068Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 620 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 3 uM ursolic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1873613Cytotoxicity against human HEK-293T cells overexpressing ACE2 assessed as maximal non-toxic dose incubated for 4 hrs2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors.
AID1873612Antiviral activity against pseudovirus SARS-CoV-2 spike protein infected in HEK-293T cells overexpressing ACE2 assessed as inhibition on pseudovirus infection incubated for 52 hrs by luminescence based microplate reader analysis2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors.
AID1888480Inhibition of yeast alpha-glucosidase at 100 uM2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Towards multi-target antidiabetic agents: In vitro and in vivo evaluation of 3,5-disubstituted indolin-2-one derivatives as novel α-glucosidase inhibitors.
AID1662168Inhibition of alpha-glucosidase (unknown origin) using p-NPG as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Anti-diabetic drugs recent approaches and advancements.
AID1497888Inhibition of almond beta-glucosidase at 120 uM using p-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1465092Mixed-type inhibition of porcine pancreatic alpha-amylase assessed as inhibitor-enzyme complex using starch as substrate by Lineweaver-Burk plot analysis2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1467130Inhibition of alpha glucosidase (unknown origin) using PNPG as substrate preincubated for 15 to 20 mins followed by substrate addition measured after 45 to 60 mins by spectrophotometric method2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Synthesis and α-glucosidase inhibition activity of dihydroxy pyrrolidines.
AID1576418Effect on growth of Bacteroides dorei JRO3 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of glucose by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1465079Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 4958 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 29.8 uM betulinic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1576403Effect on growth of Bacteroides dorei JRO1 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of glucose by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1617184Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl alpha-D-glucoside as substrate incubated for 0.5 hrs followed by substrate addition and measured after 1 hr by colorimetric assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Dasymaschalolactams A-E, Aristolactams from a Twig Extract of
AID1447209Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 2.5 mg/mL preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID1331255Inhibition of pig pancreas alpha-amylase using potato starch as substrate at 200 uM after 15 mins2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
New polyhydroxytriterpenoid derivatives from fruits of Terminalia chebula Retz. and their α-glucosidase and α-amylase inhibitory activity.
AID1398127Inhibition of almond beta-glucosidase at 120 uM using PNPG as substrate after 3 mins by UV-vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1447202Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 10 mg/mL preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID1370496Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitro-phenyl-alpha-D-glucopyranoside as substrate at 200 uM preincubated with enzyme followed by substrate addition measured after 10 mins for every 2.5 to 5 mins relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Chemical constituents from Taraxacum officinale and their α-glucosidase inhibitory activities.
AID1498908Inhibition of baker's yeast alpha-glucosidase using pNPG as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by spectrophotometric method2018Bioorganic & medicinal chemistry, 07-30, Volume: 26, Issue:13
Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.
AID1478397Inhibition of yeast alpha-glucosidase pre-incubated for 10 mins before pNPG substrate addition and measured after 30 mins2017Journal of natural products, 03-24, Volume: 80, Issue:3
α-Glucosidase Inhibitors from Preussia minimoides ‡.
AID1465050Inhibition of porcine pancreatic alpha-amylase using starch as substrate preincubated for 15 mins followed by substrate addition measured after 10 mins by dinitrosalicylic acid reagent based assay2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1324842Inhibition of alpha-glucosidase (unknown origin) using PNP glycoside as substrate preincubated for 30 mins followed by substrate addition after 60 mins by spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Syntheses of new 3-thiazolyl coumarin derivatives, in vitro α-glucosidase inhibitory activity, and molecular modeling studies.
AID1465096Ratio of Kis to control for porcine pancreatic alpha-amylase2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1447219Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID1866672Inhibition of yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated with enzyme for 10 mins followed by substrate addition measured after 20 mins by spectrophotometric method2022Journal of natural products, 04-22, Volume: 85, Issue:4
α-Glucosidase Inhibitors from the Stems of
AID1398125Inhibition of almond beta-glucosidase at 60 uM using PNPG as substrate after 3 mins by UV-vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1465078Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 2480 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 14.9 uM betulinic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1651515Inhibition of rat intestinal alpha-glucosidase at 0.02 mM using pNPG as substrate preincubated for 3 mins followed by substrate addition and measured after 30 mins relative to control2020Journal of natural products, 04-24, Volume: 83, Issue:4
Isolation and Structural Characterization of Specific Bacterial β-Glucuronidase Inhibitors from Noni (
AID1537165Inhibition of yeast alpha-glucosidase pre-incubated for 10 mins followed by pNPG substrate addition and measured every 30 secs for 35 mins2019Journal of natural products, 02-22, Volume: 82, Issue:2
Identification of α-Glucosidase Inhibitors in Machilus litseifolia by Combined Use of High-Resolution α-Glucosidase Inhibition Profiling and HPLC-PDA-HRMS-SPE-NMR.
AID1667137Inhibition of alpha-glucosidase (unknown origin) at 500 uM relative to control2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Synthesis and biological evaluation of chepraecoxin A derivatives as α-glucosidase inhibitors.
AID1465060Synergistic inhibition of porcine pancreatic alpha-amylase assessed as combination index at 1.3 uM preincubated for 15 mins followed by starch addition measured after 10 mins in presence of 5.7 uM urosolic acid by dinitrosalicylic acid reagent based assay2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1416317Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl alpha-D-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by spectrophotometric method2017MedChemComm, Jul-01, Volume: 8, Issue:7
Synthesis, α-glucosidase inhibition and molecular docking studies of novel thiazolidine-2,4-dione or rhodanine derivatives.
AID1339300Inhibition of Saccharomyces cerevisiae alpha-glucosidase type 1 using p-nitro-phenyl-alpha-D-glucopyranoside as substrate preincubated for 10 mins followed by substrate addition measured after 5 mins every 10 secs2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Quinazolinone derivatives: Synthesis and comparison of inhibitory mechanisms on α-glucosidase.
AID1624300Hypoglycemic activity in streptozocin-induced diabetic Kunming mouse assessed as blood glucose level at 50 mg/kg, po administered once daily for 18 days measured on day 1 post dose (Rvb = 18.86 +/- 0.7 mM)2019European journal of medicinal chemistry, Feb-15, Volume: 164Synthesis and biological evaluation of novel oleanolic acid analogues as potential α-glucosidase inhibitors.
AID1688725Toxicity in STZ-treated diabetic Sprague-Dawley rat model assessed as decrease in body weight at 60 mg/kg, po administered once daily for 28 days2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID1651896Inhibition of alpha-Glucosidase (unknown origin) using pNPG as substrate incubated for 30 mins
AID1327604Inhibition of hog pancreas alpha-amylase using starch as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by dinitrosalicylic acid color reagent-based UV-Vis spectrophotometric analysis2016Journal of natural products, 08-26, Volume: 79, Issue:8
α-Glucosidase and α-Amylase Inhibitors from Arcytophyllum thymifolium.
AID1872888Inhibition of baker's yeast alpha-glucosidase at 1 uM using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 30 mins followed by substrate addition and measured after 5 mins relative to control2022European journal of medicinal chemistry, May-05, Volume: 235Recent results from non-basic glycosidase inhibitors: How structural diversity can inform general strategies for improving inhibition potency.
AID1465086Inhibition of porcine pancreatic alpha-amylase assessed as Vmax for substrate using starch as substrate at 1.3 uM by Michaelis-Menten plot analysis (Rvb = 28.6 +/- 1.8 microg/ml/min)2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1354803Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-glycoside as substrate incubated for 20 mins followed by substrate addition measured immediately2018Journal of natural products, 06-22, Volume: 81, Issue:6
Peniisocoumarins A-J: Isocoumarins from Penicillium commune QQF-3, an Endophytic Fungus of the Mangrove Plant Kandelia candel.
AID1327605Inhibition of Saccharomyces cerevisiae alpha-glucosidase using 4-nitrophenyl alpha-D-glucopyranoside as substrate after 10 mins by UV-Vis spectrophotometric analysis2016Journal of natural products, 08-26, Volume: 79, Issue:8
α-Glucosidase and α-Amylase Inhibitors from Arcytophyllum thymifolium.
AID1576416Inhibition of starch utilizing system in Bacteroides dorei JRO2 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of pullulan by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1514077Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 1 mM using p-nitrophenyl beta-D-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition and measured after 15 mins relative to control2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Synthesis, in vitro and in vivo evaluation of 2-aryl-4H-chromene and 3-aryl-1H-benzo[f]chromene derivatives as novel α-glucosidase inhibitors.
AID1398121Inhibition of Saccharomyces cerevisiae alpha-glucosidase using PNPG as substrate after 3 mins by UV-vis spectrophotometric method2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1465070Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 2480 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 12.1 uM ursolic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1328534Inhibition of bakers yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate incubated for 15 mins followed by substrate addition measured after 30 mins by spectrophotometric analysis2016Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23
Synthesis and biological evaluation of novel 2,4,5-triarylimidazole-1,2,3-triazole derivatives via click chemistry as α-glucosidase inhibitors.
AID1624224Inhibition of yeast alpha-glucosidase using p-nitrophenylglucopyranoside as substrate preincubated for 10 mins followed by substrate addition and measured after 20 mins by spectrophotometric method2019Bioorganic & medicinal chemistry letters, 03-01, Volume: 29, Issue:5
Design and synthesis of new fused carbazole-imidazole derivatives as anti-diabetic agents: In vitro α-glucosidase inhibition, kinetic, and in silico studies.
AID1662175Inhibition of baker's yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 5 mins2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Anti-diabetic drugs recent approaches and advancements.
AID1697235Hypoglycemic activity in Kunming mouse assessed as reduction in maltose-induced postprandial blood glucose level measured after 15 to 120 mins by maltose loading test2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Exploring efficacy of natural-derived acetylphenol scaffold inhibitors for α-glucosidase: Synthesis, in vitro and in vivo biochemical studies.
AID1354802Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 200 uM using p-nitrophenyl-glycoside as substrate incubated for 20 mins followed by substrate addition measured immediately relative to control2018Journal of natural products, 06-22, Volume: 81, Issue:6
Peniisocoumarins A-J: Isocoumarins from Penicillium commune QQF-3, an Endophytic Fungus of the Mangrove Plant Kandelia candel.
AID1465069Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 1240 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 6.1 uM ursolic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1766976Inhibition of yeast Alpha-glucosidase using p-nitro phenyl-alpha-D-glucopyranoside as a substrate measured after 20 mins by spectrophotocolorimetric analysis2021Journal of natural products, 05-28, Volume: 84, Issue:5
α-Glucosidase Inhibitors from
AID1509463Inhibition of yeast alpha-glucosidase using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins2019European journal of medicinal chemistry, Aug-15, Volume: 176Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1576402Effect on growth of Bacteroides dorei JRO1 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of maltose by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1859109Inhibition of alpha-glucosidase (unknown origin)2022European journal of medicinal chemistry, Feb-05, Volume: 229Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
AID1497876Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 20 uM using 4-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1576404Inhibition of starch utilization system in Bacteroides dorei JRO3 assessed as bacterial growth at 5 uM after 13.5 hrs in presence of pullulan by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1697236Hypoglycemic activity in Kunming mouse assessed as reduction in maltose-induced blood glucose AUC (0 to 120 mins) by maltose loading test2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Exploring efficacy of natural-derived acetylphenol scaffold inhibitors for α-glucosidase: Synthesis, in vitro and in vivo biochemical studies.
AID1654052Induction of hypo glycemic activity in ICR mouse assessed as reduction in postprandial glucose level at 10 mg/kg, po pretreated for 30 mins followed by sucrose treatment and measured after 30 to 120 mins
AID1566356Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated with enzyme for 10 mins followed by substrate addition and measured after 30 mins by spectrophotometry2019Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23
Design, synthesis, in vitro, and in silico studies of novel diarylimidazole-1,2,3-triazole hybrids as potent α-glucosidase inhibitors.
AID1398124Inhibition of almond beta-glucosidase at 40 uM using PNPG as substrate after 3 mins by UV-vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1465071Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 24958 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 24.3 uM ursolic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1465067Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 4958 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 71.1 uM oleanolic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1332880Inhibition of Baker's yeast alpha-glucosidase using pNGP as substrate after 30 mins by spectrophotometric analysis2016European journal of medicinal chemistry, Nov-10, Volume: 123Inhibitory activity evaluation and mechanistic studies of tetracyclic oxindole derivatives as α-glucosidase inhibitors.
AID1624302Hypoglycemic activity in streptozocin-induced diabetic Kunming mouse assessed as blood glucose level at 50 mg/kg, po administered once daily for 18 days measured on day 12 post dose (Rvb = 23.09 +/- 1.45 mM)2019European journal of medicinal chemistry, Feb-15, Volume: 164Synthesis and biological evaluation of novel oleanolic acid analogues as potential α-glucosidase inhibitors.
AID1677810Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated with enzyme for 5 mins followed by substrate addition and measured after 30 mins by microplate reader analysis2020Bioorganic & medicinal chemistry, 11-01, Volume: 28, Issue:21
Indole acrylonitriles as potential anti-hyperglycemic agents: Synthesis, α-glucosidase inhibitory activity and molecular docking studies.
AID1654050Inhibition of Saccharomyces cerevisiae alpha-glucosidase using pNPG as substrate preincubated for 10 mins followed by substrate addition after 20 mins
AID1497881Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 180 uM using 4-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1398120Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 120 uM using PNPG as substrate after 3 mins by UV-vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1576417Inhibition of starch utilizing system in Bacteroides dorei JRO2 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of potato starch by spectrophotometric analysis relative to untreated con2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1576407Inhibition of starch utilization system in Bacteroides dorei JRO3 assessed as bacterial growth at 0.5 uM after 13.5 hrs in presence of pullulan by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1603597Inhibition of alpha-amylase (unknown origin) assessed as reduction in conversion of starch to glucose at 0.13 mM incubated for 1 hr relative to control2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
In vitro and in silico elucidation of antidiabetic and anti-inflammatory activities of bioactive compounds from Momordica charantia L.
AID1381559Inhibition of human alpha-glucosidase expressed in Saccharomyces cerevisiae using p-nitrophenyl-alpha-D-glucopyranoside as substrate after 15 mins
AID1892582Inhibition of Saccharomyces cerevisiae Alpha-glucosidase using p-nitrophenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition and measured for 30 mins2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Novel Hydroxychalcone-Based Dual Inhibitors of Aldose Reductase and α-Glucosidase as Potential Therapeutic Agents against Diabetes Mellitus and Its Complications.
AID1491172Inhibition of yeast alpha-glucosidase using p-nitrophenyl-alpha-glucopyranoside as substrate measured after 30 mins
AID1427929Inhibition of baker's yeast alpha-glucosidase using p-nitrophenyl alpha-D-glucopyranoside as substrate preincubated for 10 mins followed by substrate addition measured for 15 mins2017European journal of medicinal chemistry, Feb-15, Volume: 127A novel class of α-glucosidase and HMG-CoA reductase inhibitors from Ganoderma leucocontextum and the anti-diabetic properties of ganomycin I in KK-A
AID1465072Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 620 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 4.3 uM corosolic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1663506Hypoglycemic activity in starch administered mouse assessed as reduction in post prandial blood glucose level at 25 mg/kg, po measured after 60 mins relative to control2020Bioorganic & medicinal chemistry letters, 08-01, Volume: 30, Issue:15
3,4-Dihydroxyphenethyl nitrate with nitric oxide releasing, antioxidant, hypoglycemic and hypolipidemic effects.
AID1447217Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 0.00391 mg/mL preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID1697219Inhibition of alpha-glucosidase (unknown origin)2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Exploring efficacy of natural-derived acetylphenol scaffold inhibitors for α-glucosidase: Synthesis, in vitro and in vivo biochemical studies.
AID1845746Inhibition of yeast alpha-glucosidase using pnitrophenyl-a-D-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 5 mins by absorbance based assay2021Bioorganic & medicinal chemistry, 02-15, Volume: 32A comprehensive review on the biological interest of quinoline and its derivatives.
AID1688724Decrease in post prandial glucose level in type 2 diabetic Sprague-Dawley rat model at 60 mg/kg, po administered once daily for 28 days2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID1821406Inhibition of Saccharomyces cerevisiae alpha-glucosidase using pNPG as substrate assessed as release of p-nitrophenol preincubated for 18 mins followed by substrate addition and measured after 30 mins by colorimetric method2022Journal of natural products, 01-28, Volume: 85, Issue:1
Structures and Biological Activities of Polyacylated
AID1809742Inhibition of Saccharomyces cerevisiae alpha-glucosidase assessed as decrease in release of p-nitrophenol using pNPG as substrate preincubated for 15 min followed by substrate addition and measured after 5 mins by spectrophotometric method2021Bioorganic & medicinal chemistry letters, 11-15, Volume: 52Design, synthesis and biological evaluation of novel (E)-2-benzylidene-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)hydrazine-1-carboxamide derivatives as α-glucosidase inhibitors.
AID1651512Inhibition of porcine pancreatic alpha-amylase at 10 ug/ml using potato starch as substrate preincubated for 5 mins followed by substrate addition and measured after 3 mins by DNS method relative to control2020Journal of natural products, 04-24, Volume: 83, Issue:4
Isolation and Structural Characterization of Specific Bacterial β-Glucuronidase Inhibitors from Noni (
AID1824777Inhibition of Saccharomyces cerevisiae alpha-glucosidase assessed as reduction in PNP formation using alpha-PNPG as substrate incubated for 30 mins by microplate reader assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Hexahydroazulene-2(1
AID1465057Synergistic inhibition of porcine pancreatic alpha-amylase assessed as combination index at 2.6 uM preincubated for 15 mins followed by starch addition measured after 10 mins in presence of 15.6 uM corosolic acid by dinitrosalicylic acid reagent based ass2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1465077Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 1240 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 7.4 uM betulinic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1722075Inhibition of alpha-glucosidase (unknown origin)2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Synthesis, α-glucosidase inhibition, and molecular docking studies of novel N-substituted hydrazide derivatives of atranorin as antidiabetic agents.
AID1597867Inhibition of Saccharomyces cerevisiae alpha-glucosidase using para-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition and measured after 5 mins2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Synthesis of quinoline derivatives as diabetic II inhibitors and molecular docking studies.
AID1497882Inhibition of Saccharomyces cerevisiae alpha-glucosidase using 4-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1592000Competitive inhibition of Saccharomyces cerevisiae alpha-glucosidase incubated for 30 mins before pNPG substrate addition and measured after 10 mins by spectrophotometry based Michaelis-Menten equation and Lineweaver-Burk plot analysis2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
α-Glucosidase inhibition activity and in silico study of 2-(benzo[d][1,3]dioxol-5-yl)-4H-chromen-4-one, a synthetic derivative of flavone.
AID1497880Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 120 uM using 4-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1465094Mixed-type inhibition of porcine pancreatic alpha-amylase assessed as inhibitor-enzyme-substrate complex using starch as substrate by Lineweaver-Burk plot analysis2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1695077Hypoglycemic activity in C57BL/6 mouse assessed as reduction in sucrose-induced postprandial blood glucose level at 50 mg/kg, po administered via gavage and measured after 15 to 90 mins by oral sucrose loading test2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Arylsulfonyl histamine derivatives as powerful and selective α-glucosidase inhibitors.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1663498Inhibition of Saccharomyces cerevisiae alpha-glucosidase2020Bioorganic & medicinal chemistry letters, 08-01, Volume: 30, Issue:15
3,4-Dihydroxyphenethyl nitrate with nitric oxide releasing, antioxidant, hypoglycemic and hypolipidemic effects.
AID1662174Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 5 mins by spectrophotometric analysis2020Bioorganic & medicinal chemistry, 03-01, Volume: 28, Issue:5
Anti-diabetic drugs recent approaches and advancements.
AID1566357Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated with enzyme for 10 mins followed by substrate addition and measured within 20 mins by spectrophotometry2019Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23
Design, synthesis, in vitro, and in silico studies of novel diarylimidazole-1,2,3-triazole hybrids as potent α-glucosidase inhibitors.
AID1416275Inhibition of baker's yeast alpha-glucosidase preincubated for 15 to 20 mins followed by p-nitrophenyl-alpha-D-glucopyranoside substrate addition measured after 45 to 60 mins by spectrophotometric method2017MedChemComm, Aug-01, Volume: 8, Issue:8
Synthesis, molecular modeling and biological evaluation of aza-flavanones as α-glucosidase inhibitors.
AID1461511Inhibition of baker's yeast alpha-glucosidase incubated for 30 mins using p-nitrophenyl-alpha-D-glucopyranoside substrate by spectrophotometry2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis of 6-hydroxyaurone analogues and evaluation of their α-glucosidase inhibitory and glucose consumption-promoting activity: Development of highly active 5,6-disubstituted derivatives.
AID1576419Effect on growth of Bacteroides dorei JRO3 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of maltose by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1491171Inhibition of yeast alpha-glucosidase at 1.5 uM using p-nitrophenyl-alpha-glucopyranoside as substrate measured after 30 mins relative to control
AID1369349Antiobesity activity in C57BL/6J DIO mouse assessed as reduction in LEE index at 3 mg/kg administered daily via oral gavage for 5 weeks2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo.
AID1514078Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl beta-D-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition and measured after 15 mins2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Synthesis, in vitro and in vivo evaluation of 2-aryl-4H-chromene and 3-aryl-1H-benzo[f]chromene derivatives as novel α-glucosidase inhibitors.
AID1437656Antihyperglycemic activity in ICR mouse assessed as decrease in postprandial blood glucose levels at 5 mg/kg administered 30 mins followed by oral sucrose challenge measured after 30 to 120 mins by OSTT2017Journal of natural products, 01-27, Volume: 80, Issue:1
α-Glucosidase Inhibitors from Malbranchea flavorosea.
AID1383984Inhibition of alpha-amylase (unknown origin) using starch as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by dinitrosalicylic acid reagent-based assay2018European journal of medicinal chemistry, Apr-25, Volume: 1502-Aryl benzimidazoles: Synthesis, In vitro α-amylase inhibitory activity, and molecular docking study.
AID1632878Inhibition of baker's yeast alpha-glucosidase at 300 uM using p-nitrophenyl alpha-D-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured for 20 mins by spectrophotometric analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Molecular docking studies and synthesis of novel bisbenzimidazole derivatives as inhibitors of α-glucosidase.
AID1369347Antiobesity activity in C57BL/6J DIO mouse assessed as reduction in weight gain at 3 mg/kg administered daily via oral gavage for 5 weeks relative to vehicle-treated control2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo.
AID1873609Inhibition of alpha-glucosidase (unknown origin) using PNPG as substrate preincubated for 15 mins followed by substrate addition and measured after 10 mins by microplate reader analysis2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors.
AID1498907Inhibition of baker's yeast alpha-glucosidase using pNPG as substrate preincubated for 10 mins followed by substrate addition incubated for 30 mins measured up to 30 mins2018Bioorganic & medicinal chemistry, 07-30, Volume: 26, Issue:13
Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.
AID1594062Inhibition of baker's yeast alpha-glucosidase using PNPG as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins
AID1504533Inhibition of baker's yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 0.5 hrs followed by substrate addition measured for 0.5 hrs2017Journal of natural products, 12-22, Volume: 80, Issue:12
Heterodimeric Diterpenoids Isolated from Euphorbia ebracteolata Roots and Their Inhibitory Effects on α-Glucosidase.
AID1625187Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl alpha-D-glucoside as substrate by colorimetric assay2019Journal of natural products, 04-26, Volume: 82, Issue:4
α-Glucosidase Inhibitory Flavonoids and Oxepinones from the Leaf and Twig Extracts of Desmos cochinchinensis.
AID1576423Effect on growth of Bacteroides dorei JRO4 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of maltose by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1667139Inhibition of alpha-glucosidase (unknown origin)2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Synthesis and biological evaluation of chepraecoxin A derivatives as α-glucosidase inhibitors.
AID1486485Inhibition of Saccharomyces cerevisiae alpha-glucosidase pre-incubated for 10 mins before p-nitrophenyl beta-D-glucopyranoside substrate addition and measured every 30 secs for 35 mins post substrate addition2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
AID1546655Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl alpha-D-glucoside as substrate preincubated for 0.5 hrs followed substrate addition and measured after 1 hr by colorimetric method2020Journal of natural products, 01-24, Volume: 83, Issue:1
Phloroglucinol Benzophenones and Xanthones from the Leaves of
AID1663516Vasodilation activity in STZ-induced diabetic mouse assessed as increase in NO production at 25 mg/kg, po for 10 days relative to control2020Bioorganic & medicinal chemistry letters, 08-01, Volume: 30, Issue:15
3,4-Dihydroxyphenethyl nitrate with nitric oxide releasing, antioxidant, hypoglycemic and hypolipidemic effects.
AID1566630Antihyperlipidemic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as serum total cholesterol level at 50 mg/kg, po for 4 weeks (Rvb = 9.75 +/-0.11 mM)2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1654051Inhibition of rat intestinal rat alpha-glucosidase
AID1465074Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 2480 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 17.2 uM corosolic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1576411Inhibition of starch utilization system in Bacteroides dorei JRO3 assessed as reduction in bacterial growth at 0.1 uM after 14 hrs in presence of potato starch by spectrophotometric analysis2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1377531Inhibition of baker's yeast alpha-glucosidase preincubated for 10 mins followed by PNPG addition measured after 30 mins2017European journal of medicinal chemistry, Sep-29, Volume: 138Hydrazinyl arylthiazole based pyridine scaffolds: Synthesis, structural characterization, in vitro α-glucosidase inhibitory activity, and in silico studies.
AID1865588Inhibition of alpha-amylase (unknown origin)2022ACS medicinal chemistry letters, Nov-10, Volume: 13, Issue:11
Fragment-Based Dynamic Combinatorial Chemistry for Identification of Selective α-Glucosidase Inhibitors.
AID1892623Antidiabetic activity against 12 hrs fasted STZ-induced diabetic Sprague-Dawley rat model assessed as reduction in AUC of blood glucose at 80 mg/kg, IG administered once daily for 28 days followed by maltose addition after 30 mins post cpd treatment and m2022Journal of medicinal chemistry, 07-14, Volume: 65, Issue:13
Novel Hydroxychalcone-Based Dual Inhibitors of Aldose Reductase and α-Glucosidase as Potential Therapeutic Agents against Diabetes Mellitus and Its Complications.
AID1662495Inhibition of rat intestinal alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition and measured after 5 mins by spectrophotometric analysis2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Syntheses, in vitro α-amylase and α-glucosidase dual inhibitory activities of 4-amino-1,2,4-triazole derivatives their molecular docking and kinetic studies.
AID1576414Effect on growth of Bacteroides dorei JRO2 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of glucose by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1809748Hypoglycemic activity in sucrose-treated Sprague-Dawley rat assessed as reduction in blood glucose level measured after 30 mins by oral sucrose tolerance test2021Bioorganic & medicinal chemistry letters, 11-15, Volume: 52Design, synthesis and biological evaluation of novel (E)-2-benzylidene-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)hydrazine-1-carboxamide derivatives as α-glucosidase inhibitors.
AID1576408Inhibition of starch utilization system in Bacteroides dorei JRO3 assessed as bacterial growth at 1 uM after 14 hrs in presence of potato starch by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1465055Synergistic inhibition of porcine pancreatic alpha-amylase assessed as combination index at 5.3 uM preincubated for 15 mins followed by starch addition measured after 10 mins in presence of 94.1 uM oleanolic acid by dinitrosalicylic acid reagent based ass2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1371026Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside substrate incubated for 30 mins2017Journal of natural products, 04-28, Volume: 80, Issue:4
α-Glucosidase Inhibitory and Cytotoxic Taxane Diterpenoids from the Stem Bark of Taxus wallichiana.
AID1576401Inhibition of starch utilizing system in Bacteroides dorei JRO1 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of pullulan by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1498912Inhibition of Saccharomyces cerevisiae alpha-glucosidase using pNPG as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins2018Bioorganic & medicinal chemistry, 07-30, Volume: 26, Issue:13
Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.
AID1497877Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 25 uM using 4-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1752338Inhibition of Saccharomyces cerevisiae alpha-glucosidase2021Bioorganic & medicinal chemistry letters, 10-15, Volume: 50Synthesis and biological evaluation of 1,6-bis-triazole-2,3,4-tri-O-benzyl-α-d-glucopyranosides as a novel α-glucosidase inhibitor in the treatment of Type 2 diabetes.
AID1697246Inhibition of alpha-glucosidase in rat everted intestinal sleeves assessed as reduction in glucose concentration outside of the intestinal sleeves at 0.5 mM measured after 5 to 90 mins2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Exploring efficacy of natural-derived acetylphenol scaffold inhibitors for α-glucosidase: Synthesis, in vitro and in vivo biochemical studies.
AID1566632Antihyperlipidemic activity in STZ-induced type-2 diabetes Kunming mouse model assessed as serum triglyceride level at 50 mg/kg, po for 4 weeks (Rvb = 3.08 +/- 0.84 mM)2019European journal of medicinal chemistry, Sep-15, Volume: 178New insights into the biological activities of Chrysanthemum morifolium: Natural flavonoids alleviate diabetes by targeting α-glucosidase and the PTP-1B signaling pathway.
AID1697250Inhibition of alpha-glucosidase in rat everted intestinal sleeves assessed as reduction in blood glucose AUC (0-90) within intestinal sleeves at 0.5 mM2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Exploring efficacy of natural-derived acetylphenol scaffold inhibitors for α-glucosidase: Synthesis, in vitro and in vivo biochemical studies.
AID1331254Inhibition of rat intestinal alpha-glucosidase using PNPG as substrate at 200 uM after 30 mins2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
New polyhydroxytriterpenoid derivatives from fruits of Terminalia chebula Retz. and their α-glucosidase and α-amylase inhibitory activity.
AID1447208Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 5 mg/mL preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID1398117Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 40 uM using PNPG as substrate after 3 mins by UV-vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Regio- and stereospecific synthesis of rac-carbasugar-based cyclohexane pentols; Investigations of their α- and β-glucosidase inhibitions.
AID1465058Synergistic inhibition of porcine pancreatic alpha-amylase assessed as combination index at 5.3 uM preincubated for 15 mins followed by starch addition measured after 10 mins in presence of 31.2 uM corosolic acid by dinitrosalicylic acid reagent based ass2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1447222Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 4.88 10'-4mg/ml preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID1684768Inhibition of rat intestinal isomaltase2021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Elongation of the side chain by linear alkyl groups increases the potency of salacinol, a potent α-glucosidase inhibitor from the Ayurvedic traditional medicine "Salacia," against human intestinal maltase.
AID1497071Inhibition of rat intestinal alpha-glucosidase using p-nitrophenyl alpha-D-glucopyranoside as substrate pretreated for 10 mins followed by substrate addition measured after 5 mins2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Antidiabetic potential of phytochemicals isolated from the stem bark of Myristica fatua Houtt. var. magnifica (Bedd.) Sinclair.
AID1688723Antidiabetic activity against STZ-induced type 1 diabetic Sprague-Dawley rat model assessed as decrease in fasting blood glucose level at 60 mg/kg, po administered once daily for 28 days2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID1695060Competitive inhibition of Saccharomyces cerevisiae alpha-glucosidase at 0.0061 to 0.239 mM using varying levels of p-nitrophenyl-alpha-D-glucopyranoside as substrate by Lineweaver-Burk plot analysis2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Arylsulfonyl histamine derivatives as powerful and selective α-glucosidase inhibitors.
AID1684769Inhibition of rat intestinal sucrase2021Bioorganic & medicinal chemistry letters, 02-01, Volume: 33Elongation of the side chain by linear alkyl groups increases the potency of salacinol, a potent α-glucosidase inhibitor from the Ayurvedic traditional medicine "Salacia," against human intestinal maltase.
AID1435970Inhibition of human alpha-glucosidase expressed in Saccharomyces cerevisiae using p-nitophenyl-alpha-glucopyranoside as substrate pretreated with substrate for 15 mins followed by enzyme addition measured after 15 mins
AID1872867Inhibition of alpha-amyloglucosidase (unknown origin) assessed as reduction in conversion of starch to glucose using starch as substrate preincubated with substrate for 20 mins followed by enzyme addition and measured after 30 mins2022European journal of medicinal chemistry, May-05, Volume: 235Recent results from non-basic glycosidase inhibitors: How structural diversity can inform general strategies for improving inhibition potency.
AID1491046Inhibition of rat intestinal alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate pretreated for 10 mins followed by substrate addition measured after 30 mins2017Journal of natural products, 05-26, Volume: 80, Issue:5
α-Glucosidase Inhibitors from Salvia circinata.
AID1465080Inhibition of porcine pancreatic alpha-amylase assessed as Km for substrate using starch as substrate at 1.3 uM by Michaelis-Menten plot analysis (Rvb = 2.48 +/- 0.24 mg/ml)2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1447221Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 9.77 10'-4mg/ml preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID1465052Synergistic inhibition of porcine pancreatic alpha-amylase assessed as combination index at 1.3 uM preincubated for 15 mins followed by starch addition measured after 10 mins in presence of 7.8 uM corosolic acid by dinitrosalicylic acid reagent based assa2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1331252Inhibition of Saccharomyces cerevisiae alpha-glucosidase using PNPG as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
New polyhydroxytriterpenoid derivatives from fruits of Terminalia chebula Retz. and their α-glucosidase and α-amylase inhibitory activity.
AID1888481Inhibition of yeast alpha-glucosidase2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Towards multi-target antidiabetic agents: In vitro and in vivo evaluation of 3,5-disubstituted indolin-2-one derivatives as novel α-glucosidase inhibitors.
AID1465063Synergistic inhibition of porcine pancreatic alpha-amylase assessed as combination index at 10.5 uM preincubated for 15 mins followed by starch addition measured after 10 mins in presence of 45.2 uM urosolic acid by dinitrosalicylic acid reagent based ass2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1465056Synergistic inhibition of porcine pancreatic alpha-amylase assessed as combination index at 10.5 uM preincubated for 15 mins followed by starch addition measured after 10 mins in presence of 188.2 uM oleanolic acid by dinitrosalicylic acid reagent based a2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1882381Inhibition of human saliva alpha-amylase using starch as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins2022Bioorganic & medicinal chemistry, Jan-06, Volume: 55Identification of potent α-amylase inhibitors via dynamic combinatorial chemistry.
AID1663513Hypoglycemic activity in STZ-induced diabetic mouse assessed as reduction in blood glucose level at 25 mg/kg, po for 10 days relative to control2020Bioorganic & medicinal chemistry letters, 08-01, Volume: 30, Issue:15
3,4-Dihydroxyphenethyl nitrate with nitric oxide releasing, antioxidant, hypoglycemic and hypolipidemic effects.
AID1497878Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 45 uM using 4-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1697217Inhibition of alpha-glucosidase in rat everted intestinal sleeves assessed as reduction in glucose concentration within intestinal sleeves at 0.5 mM measured for 5 to 90 mins2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Exploring efficacy of natural-derived acetylphenol scaffold inhibitors for α-glucosidase: Synthesis, in vitro and in vivo biochemical studies.
AID1416003Inhibition of human alpha-amylase at 50 ug/ml using starch as substrate preincubated for 30 mins by 3,5-dinitrosalicylic acid color reagent based assay relative to control2017MedChemComm, Jul-01, Volume: 8, Issue:7
Synthesis of novel inhibitors of α-amylase based on the thiazolidine-4-one skeleton containing a pyrazole moiety and their configurational studies.
AID1576421Inhibition of starch utilizing system in Bacteroides dorei JRO3 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of potato starch by spectrophotometric analysis relative to untreated con2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1465059Synergistic inhibition of porcine pancreatic alpha-amylase assessed as combination index at 10.5 uM preincubated for 15 mins followed by starch addition measured after 10 mins in presence of 62.4 uM corosolic acid by dinitrosalicylic acid reagent based as2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1497879Inhibition of Saccharomyces cerevisiae alpha-glucosidase at 80 uM using 4-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1427930Inhibition of alpha-glucosidase in rat small intestinal mucosa assessed as reduction in glucose production using p-nitrophenyl alpha-D-glucopyranoside as substrate measured after 40 mins by glucose oxidase assay2017European journal of medicinal chemistry, Feb-15, Volume: 127A novel class of α-glucosidase and HMG-CoA reductase inhibitors from Ganoderma leucocontextum and the anti-diabetic properties of ganomycin I in KK-A
AID1360816Inhibition of Saccharomyces cerevisiae alpha-glucosidase using para-nitrophenyl glucopyranoside as substrate preincubated for 10 mins followed by substrate addition and measured after 20 mins by spectrophotometric method2018European journal of medicinal chemistry, Jul-15, Volume: 155New 6-amino-pyrido[2,3-d]pyrimidine-2,4-diones as novel agents to treat type 2 diabetes: A simple and efficient synthesis, α-glucosidase inhibition, molecular modeling and kinetic study.
AID1465066Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 2480 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 35.6 uM oleanolic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1465051Inhibition of yeast alpha-glucosidase using 4-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 20 mins2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1497884Inhibition of almond beta-glucosidase at 20 uM using p-nitrophenyl D-glucopyranoside as substrate after 3 mins by UV/Vis spectrophotometric method relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors.
AID1758963Inhibition of Alpha-glucosidase (unknown origin)2021Bioorganic & medicinal chemistry letters, 05-15, Volume: 40Dibenzazepine-linked isoxazoles: New and potent class of α-glucosidase inhibitors.
AID1497070Inhibition of porcine pancreatic alpha-amylase using starch as substrate after 30 mins by iodine reagent based assay2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Antidiabetic potential of phytochemicals isolated from the stem bark of Myristica fatua Houtt. var. magnifica (Bedd.) Sinclair.
AID1695053Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-o-D-glucopyranoside as substrate measured for 10 mins by microplate assay2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Arylsulfonyl histamine derivatives as powerful and selective α-glucosidase inhibitors.
AID1487138Inhibition of yeast alpha-glucosidase using 4-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Phenylsulfonylfuroxan NO-donor phenols: Synthesis and multifunctional activities evaluation.
AID1576400Inhibition of starch utilizing system in Bacteroides dorei JRO1 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of potato starch by spectrophotometric analysis relative to untreated con2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1465064Synergistic inhibition of yeast alpha-glucosidase assessed as combination index at 620 uM preincubated for 15 mins followed by 4-nitrophenyl-alpha-D-glucopyranoside addition measured after 20 mins in presence of 8.9 uM oleanolic acid2017Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
Pentacyclic triterpenes as α-glucosidase and α-amylase inhibitors: Structure-activity relationships and the synergism with acarbose.
AID1663500Inhibition of rat intestinal sucrase2020Bioorganic & medicinal chemistry letters, 08-01, Volume: 30, Issue:15
3,4-Dihydroxyphenethyl nitrate with nitric oxide releasing, antioxidant, hypoglycemic and hypolipidemic effects.
AID1766978Inhibition of Type-2 alpha glucosidase (unknown origin)2021Journal of natural products, 05-28, Volume: 84, Issue:5
α-Glucosidase Inhibitors from
AID1509469Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by spectrophotometric analysis2019European journal of medicinal chemistry, Aug-15, Volume: 176Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview.
AID1447218Inhibition of alpha glucosidase (unknown origin) using alpha PNPG as substrate at 0.00195 mg/mL preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2017Bioorganic & medicinal chemistry letters, 05-01, Volume: 27, Issue:9
Constituents with potent α-glucosidase inhibitory activity from Pueraria lobata (Willd.) ohwi.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1624303Hypoglycemic activity in streptozocin-induced diabetic Kunming mouse assessed as blood glucose level at 50 mg/kg, po administered once daily for 18 days measured on day 12 post dose (Rvb = 23.27 +/- 1.03 mM)2019European journal of medicinal chemistry, Feb-15, Volume: 164Synthesis and biological evaluation of novel oleanolic acid analogues as potential α-glucosidase inhibitors.
AID1576420Inhibition of starch utilizing system in Bacteroides dorei JRO3 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of pullulan by spectrophotometric analysis relative to untreated control2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1576425Inhibition of starch utilizing system in Bacteroides dorei JRO4 assessed as microbial growth at 100 uM measured at 30 mins interval with 15 secs shaking for up to 48 hrs in presence of potato starch by spectrophotometric analysis relative to untreated con2019MedChemComm, Nov-01, Volume: 10, Issue:11
Non-lethal growth inhibition by arresting the starch utilization system of clinically relevant human isolates of
AID1400153Inhibition of yeast alpha-glucosidase using 4-nitrophenyl-alpha-D-glucopyranoside as substrate incubated for 15 mins by spectrophotometric method2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Design, synthesis and in vitro study of densely functionalized oxindoles as potent α-glucosidase inhibitors.
AID1869746Inhibition of Saccharomyces cerevisiae alpha-glucosidase using pNPG as substrate preincubated for 5 mins followed by pNPG addition and measured after 10 mins by microplate reader method
AID1757079Inhibition of Saccharomyces cerevisiae alpha-glucosidase assessed as reduction in PNP formation using alpha-PNPG as substrate incubated for 30 mins2021European journal of medicinal chemistry, Apr-15, Volume: 2162,5-Disubstituted furan derivatives containing 1,3,4-thiadiazole moiety as potent α-glucosidase and E. coli β-glucuronidase inhibitors.
AID1873346Inhibition of alpha-amylase (unknown origin) assessed as reduction in conversion of starch to glucose preincubated for 10 mins followed by substrate addition and measured after 20 mins by DNSA reagent based spectrophotometric analysis2022Bioorganic & medicinal chemistry letters, 08-01, Volume: 69New pyrazole-tetrazole hybrid compounds as potent α-amylase and non-enzymatic glycation inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1801577In-vitro Yeast α-Glucosidase Inhibition Assay from Article 10.1016/j.bioorg.2016.01.008: \\Dihydropyrano [2,3-c] pyrazole: Novel in vitro inhibitors of yeast a-glucosidase.\\2016Bioorganic chemistry, Apr, Volume: 65Dihydropyrano [2,3-c] pyrazole: Novel in vitro inhibitors of yeast α-glucosidase.
AID1801563alpha-Glucosidase Inhibition Assay from Article 10.1111/cbdd.12666: \\Synthesis, In vitro and Docking Studies of New Flavone Ethers as a-Glucosidase Inhibitors.\\2016Chemical biology & drug design, Mar, Volume: 87, Issue:3
Synthesis, In vitro and Docking Studies of New Flavone Ethers as α-Glucosidase Inhibitors.
AID1801948α-Glucosidase inhibition assay from Article 10.1016/j.bioorg.2016.08.011: \\A simple and efficient synthesis of novel inhibitors of alpha-glucosidase based on benzimidazole skeleton and molecular docking studies.\\2016Bioorganic chemistry, 10, Volume: 68A simple and efficient synthesis of novel inhibitors of alpha-glucosidase based on benzimidazole skeleton and molecular docking studies.
AID1798320In Vitro alpha-Amylase Activity Assay from Article 10.1021/jm800115x: \\Flavonoids for controlling starch digestion: structural requirements for inhibiting human alpha-amylase.\\2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Flavonoids for controlling starch digestion: structural requirements for inhibiting human alpha-amylase.
AID1801603Assay for α-Glucosidase Inhibitory Activity from Article 10.1016/j.bioorg.2016.02.004: \\Synthesis, a-glucosidase inhibitory, cytotoxicity and docking studies of 2-aryl-7-methylbenzimidazoles.\\2016Bioorganic chemistry, Apr, Volume: 65Synthesis, α-glucosidase inhibitory, cytotoxicity and docking studies of 2-aryl-7-methylbenzimidazoles.
AID1803327Inhibition Assay from Article 10.3109/14756366.2012.727812: \\Pyrimidine-fused heterocycle derivatives as a novel class of inhibitors for a-glucosidase.\\2013Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 28, Issue:6
Pyrimidine-fused heterocycle derivatives as a novel class of inhibitors for α-glucosidase.
AID1803326α-glucosidase Inhibitory Activity Assay from Article 10.3109/14756366.2012.719503: \\Structure-activity relationships of bergenin derivatives effect on a-glucosidase inhibition.\\2013Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 28, Issue:6
Structure-activity relationships of bergenin derivatives effect on α-glucosidase inhibition.
AID1802604α-Glucosidase Inhibition Assay from Article 10.1016/j.bioorg.2017.03.006: \\Synthesis, in vitro evaluation and molecular docking studies of novel amide linked triazolyl glycoconjugates as new inhibitors of a-glucosidase.\\2017Bioorganic chemistry, 06, Volume: 72Synthesis, in vitro evaluation and molecular docking studies of novel amide linked triazolyl glycoconjugates as new inhibitors of α-glucosidase.
AID1802641In Vitro α-Glucosidase Inhibitory Assay from Article 10.1111/cbdd.12867: \\Synthesis, in vitro evaluation and molecular docking studies of novel coumarin-isatin derivatives as a-glucosidase inhibitors.\\2017Chemical biology & drug design, 03, Volume: 89, Issue:3
Synthesis, in vitro evaluation and molecular docking studies of novel coumarin-isatin derivatives as α-glucosidase inhibitors.
AID1801645In vitro Assay of alpha-Glucosidasee Inhibitory Activity from Article 10.1016/j.bioorg.2016.03.001: \\Design, synthesis and biological evaluation of novel coumarin thiazole derivatives as a-glucosidase inhibitors.\\2016Bioorganic chemistry, Apr, Volume: 65Design, synthesis and biological evaluation of novel coumarin thiazole derivatives as α-glucosidase inhibitors.
AID1802595α-Glucosidase Inhibition Assay from Article 10.1016/j.bioorg.2017.02.003: \\Green synthesis, inhibition studies of yeast a-glucosidase and molecular docking of pyrazolylpyridazine amines.\\2017Bioorganic chemistry, 04, Volume: 71Green synthesis, inhibition studies of yeast α-glucosidase and molecular docking of pyrazolylpyridazine amines.
AID1802894α-Glucosidase Inhibition Assay from Article 10.1016/j.bioorg.2017.05.009: \\Hetarylcoumarins: Synthesis and biological evaluation as potent a-glucosidase inhibitors.\\2017Bioorganic chemistry, 08, Volume: 73Hetarylcoumarins: Synthesis and biological evaluation as potent α-glucosidase inhibitors.
AID1801529Baker's Yeast α-Glucosidase Inhibition Assay from Article 10.1016/j.bioorg.2015.11.006: \\Benzimidazole derivatives as new a-glucosidase inhibitors and in silico studies.\\2016Bioorganic chemistry, Feb, Volume: 64Benzimidazole derivatives as new α-glucosidase inhibitors and in silico studies.
AID1801484α-Glucosidase Assay from Article 10.1016/j.bioorg.2015.09.008: \\Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast a-glucosidase, a2015Bioorganic chemistry, Dec, Volume: 63Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast α-glucosidase, acetylcholinesterase and butyrylcholinesterase.
AID1802682Enzyme Activity Assay from Article 10.1186/1471-2091-13-3: \\Enzymatic activity and immunoreactivity of Aca s 4, an alpha-amylase allergen from the storage mite Acarus siro.\\2012BMC biochemistry, Jan-31, Volume: 13Enzymatic activity and immunoreactivity of Aca s 4, an alpha-amylase allergen from the storage mite Acarus siro.
AID1802577Baker's Yeast α-Glucosidase Inhibition Assay from Article 10.1016/j.bioorg.2016.12.009: \\Synthesis, molecular docking studies of hybrid benzimidazole as a-glucosidase inhibitor.\\2017Bioorganic chemistry, 02, Volume: 70Synthesis, molecular docking studies of hybrid benzimidazole as α-glucosidase inhibitor.
AID1802588α-Glucosidase Inhibition Assay from Article 10.1016/j.bioorg.2017.01.017: \\In search of new a-glucosidase inhibitors: Imidazolylpyrazole derivatives.\\2017Bioorganic chemistry, 04, Volume: 71In search of new α-glucosidase inhibitors: Imidazolylpyrazole derivatives.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1196906Inhibition of alpha-glucosidase (unknown origin) using pNPG substrate incubated for 15 mins by microplate reader based method2015European journal of medicinal chemistry, Mar-06, Volume: 92Synthesis of novel inhibitors of α-glucosidase based on the benzothiazole skeleton containing benzohydrazide moiety and their molecular docking studies.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID594100Inhibition of rat small intestinal sucrase after 30 mins by glucose-oxidase method2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Biological evaluation of 3'-O-alkylated analogs of salacinol, the role of hydrophobic alkyl group at 3' position in the side chain on the α-glucosidase inhibitory activity.
AID620763Inhibition of mouse his-tagged ctSI expressed in Sf9 cells assessed as amount of glucose produced using maltose as a substrate after 45 mins by glucose oxidase assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID1064621Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 10 mins measured after 30 mins2014Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3
Synthesis of novel indenoquinoxaline derivatives as potent α-glucosidase inhibitors.
AID763818Inhibition of rat intestinal maltase using maltose as substrate assessed as D-glucose release from substrate preincubated for 15 mins measured after 60 mins2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and α-glucosidase inhibitory activity evaluation of N-substituted aminomethyl-β-d-glucopyranosides.
AID1070016Inhibition of rat intestinal sucrase using p-nitrophenyl-alpha-d-glucopyranoside as substrate incubated for 10 mins prior to substrate addition measured after 5 mins by spectrophotometry2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Rat intestinal sucrase inhibition of constituents from the roots of Rosa rugosa Thunb.
AID342806Inhibition of rabbit muscle amylo-1,6-glucosidase at 1000 uM2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID620761Inhibition of mouse his-tagged ctMGAM-N20 expressed in Sf9 cells assessed as amount of glucose produced using maltose as a substrate after 45 mins by glucose oxidase assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID578319Inhibition of rat intestinal maltase2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Isolation, structure identification and SAR studies on thiosugar sulfonium salts, neosalaprinol and neoponkoranol, as potent α-glucosidase inhibitors.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID641055Antihyperglycemic activity in ddY mouse assessed as inhibition of sucrose-induced increase in plasma glucose level at 10 mg/kg, po administered 30 mins before sucrose challenge measured after 0.5 hrs (Rvb = 225.1 +/- 12.5 mg/dl)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii.
AID718834Inhibition of pancreatic glucosidase in Swiss mouse pancreatic extracts2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis and glycosidase inhibitory activity of novel (2-phenyl-4H-benzopyrimedo[2,1-b]-thiazol-4-yliden)acetonitrile derivatives.
AID647238Inhibition of rat intestinal alpha-glucosidase sucrase using sucrose as substrate preincubated for 10 mins prior substrate addition measured after 40 mins by spectrophotometry2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Concise synthesis of (+)-conduritol F and inositol analogues from naturally available (+)-proto-quercitol and their glucosidase inhibitory activity.
AID590735Competitive inhibition of rat alpha-glucosidase assessed as production of chromogenic p-Nitrphenol measured after 3 mins by HPLC and Michaelis-Menten equation2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Selective α-glucosidase substrates and inhibitors containing short aromatic peptidyl moieties.
AID427710Inhibition of Bacillus stearothermophilus alpha-glucosidase type IV2009Journal of natural products, Jul, Volume: 72, Issue:7
Three adducts of butenolide and apigenin glycoside from the leaves of Machilus japonica.
AID1181389Inhibition of Wistar rat intestinal isomaltase assessed as inhibition of D-glucose release at 1000 uM after 30 mins by spectrophotometry2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of α-1-C-4'-arylbutyl-L-arabinoiminofuranoses, a new class of α-glucosidase inhibitors.
AID1201035Anticancer activity against human A549 cells by MTT assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, docking and ADMET studies of novel chalcone triazoles for anti-cancer and anti-diabetic activity.
AID641059Antihyperglycemic activity in ddY mouse assessed as inhibition of sucrose-induced increase in plasma glucose level at 20 mg/kg, po administered 30 mins before sucrose challenge measured after 1 hr (Rvb = 229.9 +/- 16.2 mg/dl)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii.
AID1235896Inhibition of alpha-glucosidase (unknown origin) pre-incubated for 20 mins before p-nitrophenyl glycoside substrate addition2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Polyketides with α-Glucosidase Inhibitory Activity from a Mangrove Endophytic Fungus, Penicillium sp. HN29-3B1.
AID1201034Anticancer activity against human IMR32 cells by MTT assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, docking and ADMET studies of novel chalcone triazoles for anti-cancer and anti-diabetic activity.
AID352467Inhibition of rat intestinal alpha-glucosidase activity2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
New Labdane diterpenes as intestinal alpha-glucosidase inhibitor from antihyperglycemic extract of Hedychium spicatum (Ham. Ex Smith) rhizomes.
AID462732Inhibition of yeast alpha-glucosidase MAL12 assessed as inhibition of p-nitrophenol release by spectrophotometry2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Synthesis, biological activity, and molecular modeling studies of 1H-1,2,3-triazole derivatives of carbohydrates as alpha-glucosidases inhibitors.
AID641146Inhibition of alpha-glucosidase activity of maltase in rat small intestinal brush border membrane fraction using maltose as substrate after 30 mins2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii.
AID1168738Inhibition of rat intestinal alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside substrate by spectrophotometry2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID462734Hypoglycemic activity in maltose-fed Wistar rat assessed as reduction in postprandial blood glucose level at 50 mg/kg, po administered 15 mins before maltose challenge measured after 30 mins of maltose infusion2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Synthesis, biological activity, and molecular modeling studies of 1H-1,2,3-triazole derivatives of carbohydrates as alpha-glucosidases inhibitors.
AID1168740Anticancer activity against human MDA-MB cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID342811Inhibition of maltase in human Caco-2 cell model system after 2 hrs2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID592406Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in blood glucose level at 5 mg/kg after 1.5 hrs by oral sucrose tolerance test (RVb= 6.1 %)2011Journal of natural products, Mar-25, Volume: 74, Issue:3
(Z)-3-butylidenephthalide from Ligusticum porteri , an α-glucosidase inhibitor.
AID1201036Anticancer activity against human HepG2 cells by MTT assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, docking and ADMET studies of novel chalcone triazoles for anti-cancer and anti-diabetic activity.
AID752380Inhibition of pig pancreas soluble alpha-amylase using 4-nitrophenyl-alpha-D-maltopentaoside as substrate assessed as enzyme activity after 30 mins by spectrophotometry relative to control2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Flaxseed (Linum usitatissimum L.) extract as well as (+)-secoisolariciresinol diglucoside and its mammalian derivatives are potent inhibitors of α-amylase activity.
AID778972Inhibition of rat intestinal alpha-glucosidase using sucrose as substrate assessed as glucose formation incubated for 10 mins prior to substrate addition measured after 30 mins by glucose oxidase method2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
α-Glucosidase-inhibitory iminosugars from the leaves of Suregada glomerulata.
AID620770Selectivity ratio of Ki for mouse ctSI to Ki for mouse ctMGAM-N202011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID685083Inhibition of yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate compound pre-incubated for 10 mins before substrate addition measured after 5 mins by microplate reader2012Journal of natural products, Aug-24, Volume: 75, Issue:8
α-Glucosidase inhibitory hydrolyzable tannins from Eugenia jambolana seeds.
AID342797Inhibition of rat intestinal brush border membrane sucrase2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID768171Inhibition of rat intestine sucrase using sucrose as substrate incubated for 10 mins prior to substrate addition measured after 40 mins by glucose oxidase colorimetric method2013European journal of medicinal chemistry, Aug, Volume: 66Quercitylcinnamates, a new series of antidiabetic bioconjugates possessing α-glucosidase inhibition and antioxidant.
AID778965Hypoglycemic effect in starch-challenged ICR mouse assessed as blood glucose level at 10 mg/kg, po after 120 mins by glucose oxidase method (Rvb = 174.2 +/- 22.9 mg/dL)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
α-Glucosidase-inhibitory iminosugars from the leaves of Suregada glomerulata.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID620762Inhibition of human ntMGAM expressed in Drosophila S2 cells assessed as amount of glucose produced using maltose as a substrate after 45 mins by glucose oxidase assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID763817Inhibition of rat intestinal sucrase using sucrose as substrate assessed as D-glucose release from substrate preincubated for 15 mins measured after 60 mins2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and α-glucosidase inhibitory activity evaluation of N-substituted aminomethyl-β-d-glucopyranosides.
AID344180Antihyperglycemic activity in Wistar rat assessed as reduction in postprandial blood glucose rise at 100 mg/kg, po by carbohydrate tolerance test2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Reduction in post-prandial hyperglycemic excursion through alpha-glucosidase inhibition by beta-acetamido carbonyl compounds.
AID243535Percentage inhibition (100 uM) against Alpha glucosidase2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Biaryls and heterobiaryls as alpha-glucosidase and protein tyrosine phosphatase inhibitors.
AID379720Inhibition of Saccharomyces sp. alpha glucosidase by spectrophotometry2006Journal of natural products, Feb, Volume: 69, Issue:2
Alpha-glucosidase inhibitory anthranols, kenganthranols A-C, from the stem bark of Harungana madagascariensis.
AID422282Inhibition of Saccharomyces cerevisiae alpha glucosidase2009Journal of natural products, Feb-27, Volume: 72, Issue:2
Polyoxygenated methyl cyclohexanoids from a terrestrial ampelomyces fungus.
AID592245Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as lowering of blood glucose level by oral sucrose tolerance test2011Journal of natural products, Mar-25, Volume: 74, Issue:3
(Z)-3-butylidenephthalide from Ligusticum porteri , an α-glucosidase inhibitor.
AID462735Hypoglycemic activity in maltose-fed Wistar rat assessed as reduction in postprandial blood glucose level at 50 mg/kg, po administered 15 mins before maltose challenge measured after 60 mins of maltose infusion2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Synthesis, biological activity, and molecular modeling studies of 1H-1,2,3-triazole derivatives of carbohydrates as alpha-glucosidases inhibitors.
AID724307Inhibition of Swiss mouse pancreatic glucosidase2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, crystal structure and antidiabetic activity of substituted (E)-3-(Benzo [d]thiazol-2-ylamino) phenylprop-2-en-1-one.
AID743825Inhibition of alpha-glucosidase (unknown origin) using PNPG as substrate at 25 uM incubated for 10 mins prior to substrate addition measured every 30 secs for 5 mins relative to control2013European journal of medicinal chemistry, May, Volume: 63Synthesis of novel triterpene and N-allylated/N-alkylated niacin hybrids as α-glucosidase inhibitors.
AID550397Inhibition of Wistar rat small intestine sucrase after 30 mins2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of α-glucosidase inhibitors.
AID725778Antidiabetic activity in po dosed streptzotocin-induced-diabetic Wistar rat model assessed as reduction glucose absorption at 30 mg/kg, po2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID620772Selectivity ratio of Ki for human ntSI to Ki for mouse ctSI2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID1168739Anticancer activity against human MCF7 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1236030Inhibition of baker's yeast alpha-glucosidase using PNPG as substrate assessed as p-nitrophenol release preincubated for 10 mins followed by substrate addition measured for 30 mins by microplate reader analysis2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Synthesis of new oxadiazole derivatives as α-glucosidase inhibitors.
AID592409Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in blood glucose level at 5 mg/kg after 2 hrs by oral sucrose tolerance test (RVb= -4.3 %)2011Journal of natural products, Mar-25, Volume: 74, Issue:3
(Z)-3-butylidenephthalide from Ligusticum porteri , an α-glucosidase inhibitor.
AID257318Inhibitory activity against baker's yeast alpha glucosidase2005Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24
Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors.
AID550396Inhibition of Wistar rat small intestine isomaltase at 1000 uM after 30 mins2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of α-glucosidase inhibitors.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1168741Anticancer activity against human HeLa cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID593351Inhibition of rat small intestinal maltase after 30 mins2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Role of the side chain stereochemistry in the α-glucosidase inhibitory activity of kotalanol, a potent natural α-glucosidase inhibitor.
AID1202785Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl alpha-D-glucoside as substrate preincubated for 0.5 hrs followed by substrate addition measured after 1 hr by colorimetric method2015Journal of natural products, Feb-27, Volume: 78, Issue:2
Bioactive prenylated xanthones from the young fruits and flowers of Garcinia cowa.
AID1168746Anticancer activity against human WRL68 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1143547Inhibition of rat intestinal alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside assessed as release of p-nitrophenol after 5 mins by spectrophotometric analysis2014European journal of medicinal chemistry, Jun-23, Volume: 81Synthesis and molecular docking studies of potent α-glucosidase inhibitors based on biscoumarin skeleton.
AID1240038Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenol glycoside as substrate after 30 mins by colorimetric analysis2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Novel 5-functionalized-pyrazoles: Synthesis, characterization and pharmacological screening.
AID407155Inhibition of alpha glucosidase from baker's yeast at 50 uM2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Discovery and biological evaluation of novel alpha-glucosidase inhibitors with in vivo antidiabetic effect.
AID550398Inhibition of Wistar rat small intestine cellobiase at 1000 uM after 30 mins2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of α-glucosidase inhibitors.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID641058Antihyperglycemic activity in ddY mouse assessed as inhibition of sucrose-induced increase in plasma glucose level at 20 mg/kg, po administered 30 mins before sucrose challenge measured after 0.5 hrs (Rvb = 225.1 +/- 12.5 mg/dl)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii.
AID305828Inhibition of rat intestinal alpha-glucosidase2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Diastereoselective synthesis of glycosylated prolines as alpha-glucosidase inhibitors and organocatalyst in asymmetric aldol reaction.
AID761770Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 15 mins2013Journal of natural products, Jul-26, Volume: 76, Issue:7
Xanthone glycoside constituents of Swertia kouitchensis with α-glucosidase inhibitory activity.
AID1248169Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by spectrophotometric analysis2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
Synthesis, in vitro biological activities and in silico study of dihydropyrimidines derivatives.
AID1254451Competitive inhibition of Saccharomyces cerevisiae alpha-glucosidase by multiplate reader method using p-nitrophenyl-alpha-D-glucopyranoside as substrate2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
2-Arylquinazolin-4(3H)-ones: A new class of α-glucosidase inhibitors.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID497106Inhibition of Bacillus stearothermophilus alpha glucosidase-42010Journal of natural products, Aug-27, Volume: 73, Issue:8
Proanthocyanidins from the leaves of Machilus philippinensis.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID342793Inhibition of rat intestinal brush border membrane maltase2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1064622Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate at 0.5 mM preincubated for 10 mins measured after 30 mins2014Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3
Synthesis of novel indenoquinoxaline derivatives as potent α-glucosidase inhibitors.
AID1168747Cytotoxicty against rat NRK cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID711102Inhibition of rat intestinal sucrase using sucrose as substrate2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID778968Hypoglycemic effect in sucrose-challenged ICR mouse assessed as glucose AUC at 10 mg/kg, po by glucose oxidase method (Rvb = 323.2 +/- 37.2 mg.hr/dL)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
α-Glucosidase-inhibitory iminosugars from the leaves of Suregada glomerulata.
AID729970Inhibition of yeast alpha-glucosidase using para-nitrophenyl alpha-D-glucopyranoside as substrate by spectrophotometric analysis2013European journal of medicinal chemistry, Apr, Volume: 62Fungal transformation of cedryl acetate and α-glucosidase inhibition assay, quantum mechanical calculations and molecular docking studies of its metabolites.
AID1192378Inhibition of bakers yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate after 30 mins by spectrophotometry2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Design, synthesis and docking study of novel tetracyclic oxindole derivatives as α-glucosidase inhibitors.
AID718938Inhibition of Bacillus stearothermophilus alpha-glucosidase using 4-nitrophenyl alpha-D-glucopyranoside as substrate after 30 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis of novel mono and bis-indole conduritol derivatives and their α/β-glycosidase inhibitory effects.
AID768173Inhibition of rat intestine maltase using maltose as substrate incubated for 10 mins prior to substrate addition measured after 40 mins by glucose oxidase colorimetric method2013European journal of medicinal chemistry, Aug, Volume: 66Quercitylcinnamates, a new series of antidiabetic bioconjugates possessing α-glucosidase inhibition and antioxidant.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID641148Inhibition of alpha-glucosidase activity of sucrase in rat small intestinal brush border membrane fraction using maltose as substrate after 30 mins2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii.
AID641060Antihyperglycemic activity in ddY mouse assessed as inhibition of sucrose-induced increase in plasma glucose level at 20 mg/kg, po administered 30 mins before sucrose challenge measured after 2 hrs (Rvb = 145.2 +/- 7.2 mg/dl)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii.
AID620766Selectivity ratio of Ki for human ntSI to Ki for mouse ctMGAM-N22011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID620765Selectivity ratio of Ki for human ntMGAM to Ki for mouse ctMGAM-N22011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1225509Inhibition of Saccharomyces cerevisiae alpha-glucosidase using pNPG as substrate preincubated for 10 mins followed by substrate addition measured after 20 mins by spectrophotometric analysis2015Journal of natural products, Apr-24, Volume: 78, Issue:4
α-Glucosidase Inhibitors from a Xylaria feejeensis Associated with Hintonia latiflora.
AID1181386Inhibition of Wistar rat intestinal maltase assessed as inhibition of D-glucose release after 30 mins by spectrophotometry2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of α-1-C-4'-arylbutyl-L-arabinoiminofuranoses, a new class of α-glucosidase inhibitors.
AID743826Inhibition of alpha-glucosidase (unknown origin) using PNPG as substrate at 10 uM incubated for 10 mins prior to substrate addition measured every 30 secs for 5 mins relative to control2013European journal of medicinal chemistry, May, Volume: 63Synthesis of novel triterpene and N-allylated/N-alkylated niacin hybrids as α-glucosidase inhibitors.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1070017Inhibition of rat intestinal sucrase using p-nitrophenyl-alpha-d-glucopyranoside as substrate at 1 mM incubated for 10 mins prior to substrate addition measured after 5 mins by spectrophotometry2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Rat intestinal sucrase inhibition of constituents from the roots of Rosa rugosa Thunb.
AID620771Selectivity ratio of Ki for human ntMGAM to Ki for mouse ctSI2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1157836Inhibition of yeast alpha-glucosidase (unknown origin) using para-nitrophenyl glucopyranoside as substrate preincubated for 10 mins before substrate addition measured after 30 mins by spectrophotometry2014Bioorganic & medicinal chemistry, Jul-01, Volume: 22, Issue:13
Discovery of novel oxindole derivatives as potent α-glucosidase inhibitors.
AID750844Inhibition of alpha glucosidase (unknown origin) assessed as p-nitrophenyl alpha-D-glucopyranoside conversion to p-nitrophenol after 30 mins by spectrophotometric analysis2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Bioactive dimeric carbazole alkaloids from Murraya koenigii.
AID1201031Inhibition of rat intestinal alpha-glucosidase using nitrophenyl-alpha-D-glucopyranoside by spectrophotometrically2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, docking and ADMET studies of novel chalcone triazoles for anti-cancer and anti-diabetic activity.
AID1250855Inhibition of rat intestinal Sucrase using sucrose as substrate assessed as glucose release after 40 mins by glucose oxidase method2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
New arylalkanones from Horsfieldia macrobotrys, effective antidiabetic agents concomitantly inhibiting α-glucosidase and free radicals.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID647234Inhibition of Baker's yeast Alpha-glucosidase-1 using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 10 mins prior substrate addition measured after 20 mins by spectrophotometry2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Concise synthesis of (+)-conduritol F and inositol analogues from naturally available (+)-proto-quercitol and their glucosidase inhibitory activity.
AID590733Competitive inhibition of Bacillus stearothermophilus alpha-glucosidase assessed as production of chromogenic p-Nitrphenol measured after 3 mins by HPLC and Michaelis-Menten equation2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Selective α-glucosidase substrates and inhibitors containing short aromatic peptidyl moieties.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID724305Inhibition of Swiss mouse liver glucosidase2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, crystal structure and antidiabetic activity of substituted (E)-3-(Benzo [d]thiazol-2-ylamino) phenylprop-2-en-1-one.
AID1190386Inhibition of baker's yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate incubated with enzyme for 10 mins prior to substrate challenge for 15 mins by microplate reader analysis2015Journal of natural products, Jan-23, Volume: 78, Issue:1
Erinacerins C-L, isoindolin-1-ones with α-glucosidase inhibitory activity from cultures of the medicinal mushroom Hericium erinaceus.
AID1055485Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-D-glucopyranoside as substrate assessed as p-nitrophenol formation incubated for 5 mins prior to substrate addition measured after 5 mins by spectrophotometry2013European journal of medicinal chemistry, , Volume: 70Synthesis, biological evaluation and molecular modeling studies of some novel thiazolidinediones with triazole ring.
AID752381Inhibition of immobilized rat intestinal alpha-glucosidase using 4-nitrophenyl-alpha-D-glucopyranoside as substrate assessed as enzyme activity after 30 mins by spectrophotometry relative to control2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Flaxseed (Linum usitatissimum L.) extract as well as (+)-secoisolariciresinol diglucoside and its mammalian derivatives are potent inhibitors of α-amylase activity.
AID718833Inhibition of porcine pancreatic alpha amylase using starch as substrate by Bernfeld method2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis and glycosidase inhibitory activity of novel (2-phenyl-4H-benzopyrimedo[2,1-b]-thiazol-4-yliden)acetonitrile derivatives.
AID1153367Inhibition pig alpha-amylase at 100 mg/ml pretreated for 30 mins followed by addition of 1% starch for 10 mins by spectrometer2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Graphite catalyzed solvent free synthesis of dihydropyrimidin-2(1H)-ones/thiones and their antidiabetic activity.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID342795Inhibition of rat intestinal brush border membrane isomaltase2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID718937Inhibition of almond beta-glucosidase using 4-nitrophenyl beta-D-glucopyranoside as substrate after 30 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis of novel mono and bis-indole conduritol derivatives and their α/β-glycosidase inhibitory effects.
AID1250854Inhibition of rat intestinal Maltase using maltose as substrate assessed as glucose release after 10 mins by glucose oxidase method2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
New arylalkanones from Horsfieldia macrobotrys, effective antidiabetic agents concomitantly inhibiting α-glucosidase and free radicals.
AID1250853Inhibition of baker's yeast alpha-glucosidase type-1 using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 30 mins followed by substrate addition measured after 20 mins by microplate reader analysis2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
New arylalkanones from Horsfieldia macrobotrys, effective antidiabetic agents concomitantly inhibiting α-glucosidase and free radicals.
AID718831Inhibition of intestinal glucosidase in Swiss mouse intestinal extracts2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis and glycosidase inhibitory activity of novel (2-phenyl-4H-benzopyrimedo[2,1-b]-thiazol-4-yliden)acetonitrile derivatives.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID305827Inhibition of rat intestinal alpha-glucosidase at 100 uM2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Diastereoselective synthesis of glycosylated prolines as alpha-glucosidase inhibitors and organocatalyst in asymmetric aldol reaction.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID768174Inhibition of yeast type 1 alpha-glucosidase using PNPG as substrate incubated for 10 mins prior to substrate addition measured after 20 mins by spectrophotometry2013European journal of medicinal chemistry, Aug, Volume: 66Quercitylcinnamates, a new series of antidiabetic bioconjugates possessing α-glucosidase inhibition and antioxidant.
AID593349Inhibition of rat small intestinal sucrase after 30 mins2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Role of the side chain stereochemistry in the α-glucosidase inhibitory activity of kotalanol, a potent natural α-glucosidase inhibitor.
AID1168742Cytotoxic activity against HEK293 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID778966Hypoglycemic effect in starch-challenged ICR mouse assessed as blood glucose level at 10 mg/kg, po after 60 mins by glucose oxidase method (Rvb = 243.0 +/- 29.0 mg/dL)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
α-Glucosidase-inhibitory iminosugars from the leaves of Suregada glomerulata.
AID763819Inhibition of Saccharomyces cerevisiae alpha-glucosidase assessed as 4-nitrophenol release from 4-nitrophenyl alpha-D-glucopyranoside preincubated for 15 mins measured after 15 mins2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis and α-glucosidase inhibitory activity evaluation of N-substituted aminomethyl-β-d-glucopyranosides.
AID718832Inhibition of liver glucosidase in Swiss mouse liver extracts2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis and glycosidase inhibitory activity of novel (2-phenyl-4H-benzopyrimedo[2,1-b]-thiazol-4-yliden)acetonitrile derivatives.
AID404692Inhibition of human salivary alpha-amylase2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Flavonoids for controlling starch digestion: structural requirements for inhibiting human alpha-amylase.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID779722Inhibition of alpha-glucosidase (unknown origin) using sucrose as substrate assessed as formation of glucose after 30 mins by glucose oxidase method2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Structure-activity relationships of lanostane-type triterpenoids from Ganoderma lingzhi as α-glucosidase inhibitors.
AID1180481Inhibition of Saccharomyces cerevisiae alpha-glucosidase2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Bioactive diterpenoids and flavonoids from the aerial parts of Scoparia dulcis.
AID1067178Inhibition of alpha-glucosidase (unknown origin) assessed as hydrolysis of pNP-alpha-Glu into pNP measured for 10 mins by spectrophotometric analysis2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Synthesis, nitric oxide release, and α-glucosidase inhibition of nitric oxide donating apigenin and chrysin derivatives.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID768168Antioxidant activity assessed as DPPH radical scavenging activity after 15 mins by spectrophotometry2013European journal of medicinal chemistry, Aug, Volume: 66Quercitylcinnamates, a new series of antidiabetic bioconjugates possessing α-glucosidase inhibition and antioxidant.
AID778970Hypoglycemic effect in sucrose-challenged ICR mouse assessed as blood glucose level at 10 mg/kg, po after 60 mins by glucose oxidase method (Rvb = 183.3 +/- 29.1 mg/dL)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
α-Glucosidase-inhibitory iminosugars from the leaves of Suregada glomerulata.
AID710951Inhibition of rat intestinal isomaltase using isomaltase as substrate at 1000 uM2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID671263Competitive inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate by Lineweaver-Burk plot and Dixon plot analysis2012Journal of natural products, May-25, Volume: 75, Issue:5
α-glucosidase inhibitors from Brickellia cavanillesii.
AID592341Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in blood glucose level at 5 mg/kg after 0.5 hr by oral sucrose tolerance test (RVb= 56 %)2011Journal of natural products, Mar-25, Volume: 74, Issue:3
(Z)-3-butylidenephthalide from Ligusticum porteri , an α-glucosidase inhibitor.
AID424212Inhibition of rat intestinal alpha-glucosidase at 100 uM2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Synthetic studies in butenonyl C-glycosides: Preparation of polyfunctional alkanonyl glycosides and their enzyme inhibitory activity.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID647236Inhibition of rat intestinal alpha-glucosidase maltase using maltose as substrate preincubated for 10 mins prior substrate addition measured after 40 mins by spectrophotometry2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Concise synthesis of (+)-conduritol F and inositol analogues from naturally available (+)-proto-quercitol and their glucosidase inhibitory activity.
AID317574Inhibition of rat intestinal alpha-glucosidase2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Synthesis and biological evaluation of novel 8-aminomethylated oroxylin A analogues as alpha-glucosidase inhibitors.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID620760Inhibition of mouse his-tagged ctMGAM-N2 expressed in Sf9 cells assessed as amount of glucose produced using maltose as a substrate after 45 mins by glucose oxidase assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID1075726Inhibition of alpha-glucosidase (unknown origin) using p-NPG as substrate assessed as p-nitrophenol formation incubated for 20 mins prior to substrate addition measured after 30 mins by UV-spectrophotometry2014Bioorganic & medicinal chemistry letters, Mar-15, Volume: 24, Issue:6
Potential α-glucosidase inhibitors from thermal transformation of (+)-catechin.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID592240Inhibition of yeast alpha-glucosidase assessed as inhibition of p-nitrophenyl-alpha-D-glucopyranoside substrate hydrolysis after 35 mins by spectroscopy2011Journal of natural products, Mar-25, Volume: 74, Issue:3
(Z)-3-butylidenephthalide from Ligusticum porteri , an α-glucosidase inhibitor.
AID456206Antihyperglycemic activity in overnight fasted starch-induced hyperglycemic Wistar rat assessed as decrease in plasma glucose level at 10 mg/kg, po administered 15 mins before starch challenge measured after 30 to 120 mins by glucose oxidase method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
alpha-Glucosidase inhibitory antihyperglycemic activity of substituted chromenone derivatives.
AID1161131Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-D-glucopyranoside substrate measured up to 30 mins by multiplate spectrophotometry2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Oxadiazoles and thiadiazoles: novel α-glucosidase inhibitors.
AID590734Competitive inhibition of rice alpha-glucosidase assessed as production of chromogenic p-Nitrphenol measured after 3 mins by HPLC and Michaelis-Menten equation2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Selective α-glucosidase substrates and inhibitors containing short aromatic peptidyl moieties.
AID1234422Inhibition of alpha glucosidase (unknown origin) using para-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 10 mins by spectrophotometric analysis2015Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14
Discovery of xanthine oxidase inhibitors and/or α-glucosidase inhibitors by carboxyalkyl derivatization based on the flavonoid of apigenin.
AID378186Inhibition of alpha glucosidase2005Journal of natural products, Mar, Volume: 68, Issue:3
Synthesis and biological evaluation of a natural ester sintenin and its synthetic analogues.
AID307366Inhibition of alpha-glucosidase at 1 mM2007Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12
Synthesis of andrographolide derivatives: a new family of alpha-glucosidase inhibitors.
AID778964Hypoglycemic effect in starch-challenged ICR mouse assessed as glucose AUC at 10 mg/kg, po by glucose oxidase method (Rvb = 430.1 +/- 44.7 mg.hr/dL)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
α-Glucosidase-inhibitory iminosugars from the leaves of Suregada glomerulata.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1212372Systemic absorption of acarbose estimated from drug excretion in human urine2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Tissue distribution and identification of radioactivity components at elimination phase after oral administration of [¹⁴C]CS-1036, an α-amylase inhibitor, to rats.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID593353Inhibition of rat small intestinal isomaltase after 30 mins2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Role of the side chain stereochemistry in the α-glucosidase inhibitory activity of kotalanol, a potent natural α-glucosidase inhibitor.
AID638442Inhibition of yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 10 mins before substrate addition measured after 5 mins by micro-plate reader analysis2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Maplexins, new α-glucosidase inhibitors from red maple (Acer rubrum) stems.
AID620764Inhibition of human ntSI expressed in Drosophila S2 cells assessed as amount of glucose produced using maltose as a substrate after 45 mins by glucose oxidase assay2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID724304Inhibition of pure alpha-glucosidase (unknown origin) assessed as para-nitrophenol release at 420 nm OD2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, crystal structure and antidiabetic activity of substituted (E)-3-(Benzo [d]thiazol-2-ylamino) phenylprop-2-en-1-one.
AID671261Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 5 mins prior to substrate addition measured after 35 mins by spectrophotocolorimetric assay2012Journal of natural products, May-25, Volume: 75, Issue:5
α-glucosidase inhibitors from Brickellia cavanillesii.
AID1201033Anticancer activity against human DU145 cells by MTT assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, docking and ADMET studies of novel chalcone triazoles for anti-cancer and anti-diabetic activity.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID594101Inhibition of rat small intestinal isomaltase after 30 mins by glucose-oxidase method2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Biological evaluation of 3'-O-alkylated analogs of salacinol, the role of hydrophobic alkyl group at 3' position in the side chain on the α-glucosidase inhibitory activity.
AID724308Inhibition of pig pancreatic alpha-amylase by Bernfeld method2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, crystal structure and antidiabetic activity of substituted (E)-3-(Benzo [d]thiazol-2-ylamino) phenylprop-2-en-1-one.
AID732785Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitrophenyl-alpha-D-glycopyranose as substrate after 20 mins by UV/Vis spectrophotometric analysis2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Five-membered iminocyclitol α-glucosidase inhibitors: synthetic, biological screening and in silico studies.
AID1125425Inhibition of baker's yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate incubated with enzyme for 10 mins prior to substrate challenge for 15 mins by microplate reader analysis2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Two sarcoviolins with antioxidative and α-glucosidase inhibitory activity from the edible mushroom Sarcodon leucopus collected in Tibet.
AID578320Inhibition of rat intestinal sucrase2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Isolation, structure identification and SAR studies on thiosugar sulfonium salts, neosalaprinol and neoponkoranol, as potent α-glucosidase inhibitors.
AID778971Hypoglycemic effect in sucrose-challenged ICR mouse assessed as blood glucose level at 10 mg/kg, po after 30 mins by glucose oxidase method (Rvb = 187.4 +/- 21.6 mg/dL)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
α-Glucosidase-inhibitory iminosugars from the leaves of Suregada glomerulata.
AID743823Inhibition of alpha-glucosidase (unknown origin) using PNPG as substrate at 100 uM incubated for 10 mins prior to substrate addition measured every 30 secs for 5 mins relative to control2013European journal of medicinal chemistry, May, Volume: 63Synthesis of novel triterpene and N-allylated/N-alkylated niacin hybrids as α-glucosidase inhibitors.
AID641056Antihyperglycemic activity in ddY mouse assessed as inhibition of sucrose-induced increase in plasma glucose level at 10 mg/kg, po administered 30 mins before sucrose challenge measured after 1 hr (Rvb = 229.9 +/- 16.2 mg/dl)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii.
AID1239170Inhibition of yeast alpha-glucosidase using p-NPG as substrate2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Inhibitory Effects of Highly Oxygenated Lanostane Derivatives from the Fungus Ganoderma lucidum on P-Glycoprotein and α-Glucosidase.
AID471380Inhibition of yeast alpha-glucosidase after 15 mins2009Journal of natural products, Oct, Volume: 72, Issue:10
Triterpenoid saponins from Rubus ellipticus var. obcordatus.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID595755Inhibition of yeast alpha-glucosidase assessed as p-nitrophenol release after 20 mins by microplate spectrophotometer2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID1250856Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins in dark condition by spectrophotometric analysis2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
New arylalkanones from Horsfieldia macrobotrys, effective antidiabetic agents concomitantly inhibiting α-glucosidase and free radicals.
AID1240037Inhibition of alpha-amylase (unknown origin) using starch as substrate after 30 mins by spectrophotometer analysis2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Novel 5-functionalized-pyrazoles: Synthesis, characterization and pharmacological screening.
AID752382Inhibition of rat intestinal soluble alpha-glucosidase using 4-nitrophenyl-alpha-D-glucopyranoside as substrate assessed as enzyme activity after 30 mins by spectrophotometry relative to control2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Flaxseed (Linum usitatissimum L.) extract as well as (+)-secoisolariciresinol diglucoside and its mammalian derivatives are potent inhibitors of α-amylase activity.
AID391608Inhibition of Saccharomyces cerevisiae alpha-glucosidase2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Chlorogenic acid derivatives with alkyl chains of different lengths and orientations: potent alpha-glucosidase inhibitors.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID592344Antidiabetic activity in streptozotocin-induced diabetic ICR mouse assessed as change in blood glucose level at 5 mg/kg after 1 hr by oral sucrose tolerance test (RVb= 11.4 %)2011Journal of natural products, Mar-25, Volume: 74, Issue:3
(Z)-3-butylidenephthalide from Ligusticum porteri , an α-glucosidase inhibitor.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1227999Inhibition of Saccharomyces cerevisiae alpha-glucosidase pre-incubated for 10 mins at 25 degC before addition of p-nitrophenyl-alpha-D-glucopyranoside substrate by UV absorption based assay2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Dimeric Abietane Diterpenoids and Sesquiterpenoid Lactones from Teucrium viscidum.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1168743Anticancer activity against human A498 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID323184Inhibition of Gypsophila oldhamiana alpha-glucosidase2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
New triterpenoid saponins with strong alpha-glucosidase inhibitory activity from the roots of Gypsophila oldhamiana.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1187905Inhibition of alpha-glucosidase (unknown origin) using 3 mM p-NPG solution at 50 uM relative to control2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
A new phenylpropanoid and an alkylglycoside from Piper retrofractum leaves with their antioxidant and α-glucosidase inhibitory activity.
AID1181388Inhibition of Wistar rat intestinal sucrase assessed as inhibition of D-glucose release after 30 mins by spectrophotometry2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of α-1-C-4'-arylbutyl-L-arabinoiminofuranoses, a new class of α-glucosidase inhibitors.
AID1235933Inhibition of maltase in rat intestinal mucosa pre-incubated for 40 mins using maltose substrate2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID714355Inhibition of alpha glucosidase at 1 mM using pNPG substrate incubated for 60 mins2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Synthesis and anti-hyperglycemic activity of hesperidin derivatives.
AID1172876Inhibition of rat intestinal maltase using maltose substrate incubated for 10 mins2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Amine-linked diquercitols as new α-glucosidase inhibitors.
AID342804Inhibition of rabbit glycogen phosphorylase B at 400 uM2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID418684Antidiabetic activity in po dosed type 2 diabetes mellitus patient assessed as reduction in HbA1C level in pancreas2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID594099Inhibition of rat small intestinal maltase after 30 mins by glucose-oxidase method2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Biological evaluation of 3'-O-alkylated analogs of salacinol, the role of hydrophobic alkyl group at 3' position in the side chain on the α-glucosidase inhibitory activity.
AID1234424Hypoglycemic activity in ICR mouse assessed as decrease in elevated postprandial blood glucose level at 20 mg/kg, po administered 30 mins prior to sucrose challenge measured after 30 mins by OSTT2015Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14
Discovery of xanthine oxidase inhibitors and/or α-glucosidase inhibitors by carboxyalkyl derivatization based on the flavonoid of apigenin.
AID1235931Inhibition of alpha-glucosidase in rat intestinal mucosa pre-incubated for 40 mins using p-nitrophenyl-alpha-D-glucopyranoside substrate2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID391607Inhibition of Bacillus stearothermophilus alpha-glucosidase2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Chlorogenic acid derivatives with alkyl chains of different lengths and orientations: potent alpha-glucosidase inhibitors.
AID738370Inhibition of rat alpha-amylase using amylose as substrate by colorimetric analysis2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
A new series of N2-substituted-5-(p-toluenesulfonylamino)phthalimide analogues as α-glucosidase inhibitors.
AID578321Inhibition of rat intestinal isomaltase2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Isolation, structure identification and SAR studies on thiosugar sulfonium salts, neosalaprinol and neoponkoranol, as potent α-glucosidase inhibitors.
AID1248385Inhibition of human salivary alpha-amylase using GalG2CNP as substrate by UV-Vis spectrophotometric analysis2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
From carbohydrates to drug-like fragments: Rational development of novel α-amylase inhibitors.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1235930Inhibition of Baker's yeast alpha-glucosidase2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID342802Inhibition of human lysosomal beta-glucosidase at 1000 uM2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1201032Anticancer activity against human MCF7 cells by MTT assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Synthesis, docking and ADMET studies of novel chalcone triazoles for anti-cancer and anti-diabetic activity.
AID1168745Anticancer activity against human SH-SY5Y cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1236853Inhibition of Bacillus stearothermophilus alpha-glucosidase2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Acylated glucosylflavones as α-glucosidase inhibitors from Tinospora crispa leaf.
AID311909Inhibition of yeast alpha glucosidase2007Journal of natural products, Dec, Volume: 70, Issue:12
Structure and absolute configuration of clerodane diterpene glycosides and a rearranged cadinane sesquiterpene glycoside from the stems of Tinospora sinensis.
AID738373Inhibition of Saccharomyces cerevisiae alpha-glucosidase using 4-nitrophenyl alpha D-glucopyranoside as substrate assessed as release of 4-nitrophenol incubated for 5 mins prior to substrate addition measured after 10 mins2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
A new series of N2-substituted-5-(p-toluenesulfonylamino)phthalimide analogues as α-glucosidase inhibitors.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1168744Anticancer activity against human K562 cells after 24 hrs by MTT assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID462731Inhibition of yeast alpha-glucosidase MAL12 assessed as inhibition of p-nitrophenol release at 500 uM by spectrophotometry relative to control2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Synthesis, biological activity, and molecular modeling studies of 1H-1,2,3-triazole derivatives of carbohydrates as alpha-glucosidases inhibitors.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID738371Inhibition of rat intestinal lactase using lactose as substrate by colorimetric analysis2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
A new series of N2-substituted-5-(p-toluenesulfonylamino)phthalimide analogues as α-glucosidase inhibitors.
AID1172877Inhibition of rat intestinal sucrase using sucrose substrate incubated for 10 mins2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Amine-linked diquercitols as new α-glucosidase inhibitors.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1172875Inhibition of Baker's yeast alpha-glucosidase pre-incubated for 10 mins before para-nitrophenyl-alpha-D-glucopyranoside substrate addition2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Amine-linked diquercitols as new α-glucosidase inhibitors.
AID711104Inhibition of rat intestinal maltase using moltose as substrate2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
α-1-C-butyl-1,4-dideoxy-1,4-imino-l-arabinitol as a second-generation iminosugar-based oral α-glucosidase inhibitor for improving postprandial hyperglycemia.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID743824Inhibition of alpha-glucosidase (unknown origin) using PNPG as substrate at 50 uM incubated for 10 mins prior to substrate addition measured every 30 secs for 5 mins relative to control2013European journal of medicinal chemistry, May, Volume: 63Synthesis of novel triterpene and N-allylated/N-alkylated niacin hybrids as α-glucosidase inhibitors.
AID620768Selectivity ratio of Ki for human ntMGAM to Ki for mouse ctMGAM-N202011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID1207070Inhibition of baker's yeast alpha-glucosidase2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
N-Arylmethylaminoquercitols, a new series of effective antidiabetic agents having α-glucosidase inhibition and antioxidant activity.
AID1235932Inhibition of sucrase in rat intestinal mucosa pre-incubated for 40 mins using sucrose substrate2015Journal of natural products, Aug-28, Volume: 78, Issue:8
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
AID738372Inhibition of rat intestinal maltase using maltose as substrate by colorimetric analysis2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
A new series of N2-substituted-5-(p-toluenesulfonylamino)phthalimide analogues as α-glucosidase inhibitors.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1248069Inhibition of baker's yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside as substrate after 30 mins by spectrophotometric analysis2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Synthesis, α-glucosidase inhibitory and molecular docking studies of prenylated and geranylated flavones, isoflavones and chalcones.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID778967Hypoglycemic effect in starch-challenged ICR mouse assessed as blood glucose level at 10 mg/kg, po after 30 mins by glucose oxidase method (Rvb = 278.9 +/- 33.5 mg/dL)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
α-Glucosidase-inhibitory iminosugars from the leaves of Suregada glomerulata.
AID418687Antidiabetic activity in po dosed type 2 diabetes mellitus patient assessed as reduction in HbA1C level in small intestine2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
AID1161133Competitive inhibition of alpha-glucosidase (unknown origin) by Lineweaver-Burk plot2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
Oxadiazoles and thiadiazoles: novel α-glucosidase inhibitors.
AID342799Inhibition of human lysosomal alpha-glucosidase2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.
AID724306Inhibition of Swiss mouse intestinal glucosidase2013European journal of medicinal chemistry, Jan, Volume: 59Synthesis, crystal structure and antidiabetic activity of substituted (E)-3-(Benzo [d]thiazol-2-ylamino) phenylprop-2-en-1-one.
AID620767Selectivity ratio of Ki for mouse ctSI to Ki for mouse ctMGAM-N22011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1201094Inhibition of baker's yeast alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside substrate assessed as reduction in p-nitrophenolate formation2015European journal of medicinal chemistry, Apr-13, Volume: 94Phenolic thio- and selenosemicarbazones as multi-target drugs.
AID692014Inhibition of Bacillus stearothermophilus alpha-glucosidase type 42012Journal of natural products, Oct-26, Volume: 75, Issue:10
Dibenzocycloheptanoids from the leaves of Cinnamomum subavenium.
AID550399Inhibition of Wistar rat small intestine lactase at 1000 uM after 30 mins2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of α-glucosidase inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID778969Hypoglycemic effect in sucrose-challenged ICR mouse assessed as blood glucose level at 10 mg/kg, po after 120 mins by glucose oxidase method (Rvb = 137.8 +/- 14.5 mg/dL)2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
α-Glucosidase-inhibitory iminosugars from the leaves of Suregada glomerulata.
AID620769Selectivity ratio of Ki for human ntSI to Ki for mouse ctMGAM-N202011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID550393Inhibition of Wistar rat small intestine maltase after 30 mins2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
The synthesis and biological evaluation of 1-C-alkyl-L-arabinoiminofuranoses, a novel class of α-glucosidase inhibitors.
AID1207073Antioxidant activity of the compound assessed as DPPH radical scavenging activity at 5 mg/ml incubated in dark condition for 15 mins by colorimetric method relative to control2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
N-Arylmethylaminoquercitols, a new series of effective antidiabetic agents having α-glucosidase inhibition and antioxidant activity.
AID641057Antihyperglycemic activity in ddY mouse assessed as inhibition of sucrose-induced increase in plasma glucose level at 10 mg/kg, po administered 30 mins before sucrose challenge measured after 2 hrs (Rvb = 145.2 +/- 7.2 mg/dl)2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1994The Journal of biological chemistry, Jun-03, Volume: 269, Issue:22
Refined structure for the complex of acarbose with glucoamylase from Aspergillus awamori var. X100 to 2.4-A resolution.
AID1811Experimentally measured binding affinity data derived from PDB1994The Journal of biological chemistry, Jun-03, Volume: 269, Issue:22
Refined structure for the complex of acarbose with glucoamylase from Aspergillus awamori var. X100 to 2.4-A resolution.
AID1800198Alpha-Glucosidase Assay from Article 10.1111/cbdd.12205: \\Antioxidant, a-glucosidase and xanthine oxidase inhibitory activity of bioactive compounds from maize (Zea mays L.).\\2014Chemical biology & drug design, Jan, Volume: 83, Issue:1
Antioxidant, α-glucosidase and xanthine oxidase inhibitory activity of bioactive compounds from maize (Zea mays L.).
AID1800302Glucosidase assay from Article 10.1016/j.bioorg.2014.05.003: \\Novel synthesis of dihydropyrimidines for a-glucosidase inhibition to treat type 2 diabetes: in vitro biological evaluation and in silico docking.\\2014Bioorganic chemistry, Jun, Volume: 54Novel synthesis of dihydropyrimidines for α-glucosidase inhibition to treat type 2 diabetes: in vitro biological evaluation and in silico docking.
AID1801058Alpha-glucosidase Assay from Article 10.1016/j.bioorg.2015.06.006: \\Synthesis, in vitro evaluation and molecular docking studies of thiazole derivatives as new inhibitors of a-glucosidase.\\2015Bioorganic chemistry, Oct, Volume: 62Synthesis, in vitro evaluation and molecular docking studies of thiazole derivatives as new inhibitors of α-glucosidase.
AID1800999Alpha-glucosidase Inhibition Assay from Article 10.1016/j.bioorg.2014.11.006: \\Organocatalyzed solvent free an efficient novel synthesis of 2,4,5-trisubstituted imidazoles for a-glucosidase inhibition to treat diabetes.\\2015Bioorganic chemistry, Feb, Volume: 58Organocatalyzed solvent free an efficient novel synthesis of 2,4,5-trisubstituted imidazoles for α-glucosidase inhibition to treat diabetes.
AID1801004Alpha-glucosidase Assay from Article 10.1016/j.bioorg.2014.12.001: \\Triazinoindole analogs as potent inhibitors of a-glucosidase: synthesis, biological evaluation and molecular docking studies.\\2015Bioorganic chemistry, Feb, Volume: 58Triazinoindole analogs as potent inhibitors of α-glucosidase: synthesis, biological evaluation and molecular docking studies.
AID1801048alpha-Glucosidase Assay from Article 10.1016/j.bioorg.2015.03.005: \\Isatin based Schiff bases as inhibitors of a-glucosidase: Synthesis, characterization, in vitro evaluation and molecular docking studies.\\2015Bioorganic chemistry, Jun, Volume: 60Isatin based Schiff bases as inhibitors of α-glucosidase: Synthesis, characterization, in vitro evaluation and molecular docking studies.
AID1811Experimentally measured binding affinity data derived from PDB2003Journal of biochemistry, Dec, Volume: 134, Issue:6
Effects of essential carbohydrate/aromatic stacking interaction with Tyr100 and Phe259 on substrate binding of cyclodextrin glycosyltransferase from alkalophilic Bacillus sp. 1011.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2003Journal of biochemistry, Dec, Volume: 134, Issue:6
Effects of essential carbohydrate/aromatic stacking interaction with Tyr100 and Phe259 on substrate binding of cyclodextrin glycosyltransferase from alkalophilic Bacillus sp. 1011.
AID1346070Mouse maltase-glucoamylase (3.2.1.- Glycosidases)2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Mapping the intestinal alpha-glucogenic enzyme specificities of starch digesting maltase-glucoamylase and sucrase-isomaltase.
AID771591Cytotoxicity against HFF after 72 hrs2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Synthetic chondramide A analogues stabilize filamentous actin and block invasion by Toxoplasma gondii.
AID771592Antiparasitic activity against Toxoplasma gondii expressing beta-galactosidase infected in HFF assessed as parasite growth inhibition after 72 hrs2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Synthetic chondramide A analogues stabilize filamentous actin and block invasion by Toxoplasma gondii.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (252)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (1.19)18.2507
2000's25 (9.92)29.6817
2010's177 (70.24)24.3611
2020's47 (18.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 96.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index96.53 (24.57)
Research Supply Index4.88 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index168.94 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (96.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews11 (8.40%)6.00%
Reviews2 (1.69%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other120 (91.60%)84.16%
Other116 (98.31%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (95)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy [NCT01175486]Phase 4200 participants (Anticipated)Interventional2010-07-31Recruiting
Compliance With Dietary Recommendations in Obese Diabetic Patients Undergoing Acarbose Therapy [NCT01333774]423 participants (Actual)Observational2008-05-31Completed
Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome [NCT01019356]52 participants (Actual)Interventional2006-08-31Completed
Chinese PLA General Hospital Hainan Branch [NCT03602638]Phase 4300 participants (Anticipated)Interventional2018-10-01Not yet recruiting
Acarbose in Cardiovascular Risk Management. Assessment of Clinical Efficacy and Safety of Acarbose and Its Effect on Selected Cardiovascular Risk Factors in Type 2 Diabetes Patients. [NCT01167231]3,310 participants (Actual)Observational2007-05-31Completed
Incretin-based Drugs and the Risk of Heart Failure: A Multi-center Network Observational Study [NCT02456428]1,499,650 participants (Actual)Observational2014-03-31Completed
Acarbose/Metformin Fixed Dose Combination: Treatment Patterns and Outcomes in Newly Diagnosed T2DM Patients in India [NCT04665570]2,000 participants (Actual)Observational2020-12-21Active, not recruiting
A Prospective, Randomized, Open Label, Parallel, 16-week Study to Explore and Evaluate the Therapeutic Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese P [NCT03961659]87 participants (Anticipated)Interventional2019-05-31Recruiting
The Use of Incretin-based Drugs and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes [NCT02476760]1,417,914 participants (Actual)Observational2014-03-31Completed
Effect of Endotherapy on the Progression of Chronic Pancreatitis in Painless Patients [NCT05261997]60 participants (Anticipated)Interventional2022-03-31Recruiting
Acarbose as a Safe Effective Modulator of Aging Deficits in Geriatric Subjects [NCT02865499]Phase 28 participants (Actual)Interventional2016-06-30Completed
Study of Changes in Muscle and Fat Gene Transcription With Acarbose Treatment: a Crossover Study [NCT02953093]Phase 210 participants (Actual)Interventional2017-08-30Completed
Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups [NCT00909051]15,729 participants (Actual)Observational2009-03-24Completed
Open, Prospective, Multicentric, Single-arm, Non-interventional Study to Evaluate the Effectiveness & Safety of Oral Glucobay®-M Tablets in Type 2 Diabetes Patient [NCT01219582]9,364 participants (Actual)Observational2010-10-31Completed
Research of Intensive Lifestyle Intervention for Overweight PCOS Patients With Impaired Glucose Tolerance in Their Metabolic and Reproductive Abnormalities Treatment [NCT02446834]40 participants (Actual)Interventional2015-04-30Completed
Treatment of Hypoglycemia Following Gastric Bypass Surgery [NCT02527993]Phase 411 participants (Actual)Interventional2015-10-31Completed
Research of Intensive Metabolic Intervention Before Pregnancy in Polycystic Ovary Syndrome [NCT03383068]Phase 4160 participants (Anticipated)Interventional2018-01-01Not yet recruiting
A Multicenter, Randomized, Double-Blinded, Monotherapy-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of the Acarbose and Metformin in Loose-Dose Combination Compared to Metformin Monotherapy in Subjects WithType 2 Diabetic Mellitus [NCT03349684]Phase 3287 participants (Actual)Interventional2018-03-05Completed
A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus [NCT01316861]Phase 379 participants (Actual)Interventional2012-09-30Completed
Metabolic Syndrome and Its Single Traits as Risk Factors of Diabetes in People With Impaired Glucose Tolerance: The STOP-NIDDM Trial [NCT00629213]Phase 31,429 participants InterventionalCompleted
Comparison of Efficacy and Safety of Standard vs Higher Starting Dose of Insulin Glargine in Overweight and Obese Chinese Patients With Type 2 Diabetes [NCT02836704]Phase 4892 participants (Actual)Interventional2016-09-09Completed
Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients (GetUp Trial) [NCT02500329]Phase 454 participants (Anticipated)Interventional2014-09-30Recruiting
An Open, Multi-center, Randomized Study to Evaluate the Efficacy and Safety of Mitiglinide Versus Acarbose in Patients With Type 2 Diabetes Mellitus in China [NCT02143765]Phase 4248 participants (Actual)Interventional2014-05-31Completed
Explore the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin in Chinese Type 2 Diabetes by CGMS [NCT02438397]Phase 480 participants (Anticipated)Interventional2014-12-31Recruiting
Randomized, Non-blinded Crossover Study to Establish the Bioequivalence Between Fixed Dose Combination (FDC) and the Loose Combination of Acarbose and Metformin Following Single Oral Dosing in Chinese Healthy Adult Male and Female Subjects [NCT04065581]Phase 124 participants (Actual)Interventional2019-10-14Completed
Effect of Acarbose and Fixed Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes Receiving Anti-diabetic Monotherapy [NCT05629806]Phase 350 participants (Anticipated)Interventional2022-04-10Recruiting
A Multi-center, Open-label, Randomized, Active-control, Parallel-group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug-naive Type 2 Diabetes Mellitus Patients [NCT00928889]Phase 4160 participants (Actual)Interventional2009-07-31Completed
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese T2DM Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive: A Multicenter, Randomized, Open Label, Prospective Study [NCT03794336]Phase 41,293 participants (Actual)Interventional2019-06-29Completed
A Pilot Study Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia Post-RYGB [NCT02685852]Phase 111 participants (Actual)Interventional2016-02-29Completed
A Multi-centre, Parallel, Double-blind, Randomised and Placebo Controlled Spanish Study, to Prevent or Delay the Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care (PREDIAP) [NCT01010100]Phase 3204 participants (Actual)Interventional2000-08-31Completed
The Effect of Vildagliptin on Endothelium-dependent Vasodilatation. A Double Blind Cross-over Study in Type 2 Diabetes Mellitus. [NCT01000688]Phase 316 participants (Anticipated)Interventional2010-01-31Completed
Effects of Carbohydrates on Gut Hormone Secretion After Gastric Bypass Surgery [NCT02879955]20 participants (Actual)Interventional2016-08-31Completed
Special Drug Use Investigation of Glucobay OD [NCT01685502]2,289 participants (Actual)Observational2010-11-30Completed
Postprandial Glycemia in Association With Vascular Disease in Childhood Obesity [NCT00846521]Phase 423 participants (Actual)Interventional2006-09-30Terminated
A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary S [NCT00829660]Phase 46,526 participants (Actual)Interventional2009-02-17Completed
A Randomized, Non-inferiority, Open-label Clinical Trial to Evaluate the Safety and Efficacy of GAcarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes in Chinese [NCT02605772]Phase 4100 participants (Anticipated)Interventional2015-12-31Not yet recruiting
Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation [NCT00858676]Phase 4150 participants (Anticipated)Interventional2009-04-30Recruiting
A Randomized, Parallel Group, Open-Label, Active-Controlled Study Comparing Acarbose With Voglibose in Patients Who Are Inadequately Controlled With Insulin Glargine Alone or in Combination With Metformin Based on Glycemic Control [NCT00970528]Phase 4124 participants (Actual)Interventional2009-11-30Completed
A 3-week, Multi-center, Open-label, Randomized, Active-control, Parallel-group Study to Compare Effects of Nateglinide and Acarbose on Postprandial Glucose Fluctuation in Chinese Drug-naive Patients Type 2 Diabetes Mellitus [NCT01030952]Phase 4103 participants (Actual)Interventional2009-12-31Completed
Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens: a Multicentre Randomized Parallel-group Clinical Trial [NCT02587741]Early Phase 1600 participants (Anticipated)Interventional2015-07-31Recruiting
Acarbose and Older Adults With Postprandial Hypotension [NCT01914133]Phase 242 participants (Actual)Interventional2014-01-31Completed
Glucobay M - Evaluation of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice [NCT01915264]0 participants (Actual)Observational2015-08-31Withdrawn
The Use of Acarbose to Treat Postprandial Hypotension in Older Adults With Type 2 Diabetes [NCT02043886]Phase 215 participants (Actual)Interventional2007-06-30Completed
A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD) [NCT00677521]Phase 21 participants (Actual)Interventional2007-01-31Terminated(stopped due to poor recruitment and no student currently interested in working on this project.)
An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin [NCT01025765]Phase 480 participants (Anticipated)Interventional2009-11-30Active, not recruiting
Placebo Controlled Investigation on Action of Acarbose on the Sub-Clinical Inflammation and Immune Response in Early Type 2 Diabetes and Atherosclerosis Risk [NCT00558883]Phase 3104 participants (Actual)Interventional2005-01-31Completed
Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study) [NCT00221156]Phase 3300 participants (Anticipated)Interventional2005-05-31Completed
Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy [NCT01961388]0 participants (Actual)Observational2015-08-31Withdrawn
Evaluation and Treatment of Autonomic Failure. [NCT00223691]Phase 1389 participants (Actual)Interventional2002-03-31Completed
Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes Mellitus [NCT00568074]Phase 4131 participants (Actual)Interventional2003-12-16Completed
Evaluation of Relative Bioavailability of BI 44847 in Different Ethnic Groups (Subjects of White, Asian, and African Origin), and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 4484 [NCT02211950]Phase 137 participants (Actual)Interventional2008-10-31Completed
A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therap [NCT01177384]Phase 3380 participants (Actual)Interventional2011-01-25Completed
A Non-interventional Study of Patient Medication Adherence and Treatment Effectiveness Among New Users of Linagliptin and Acarbose in the Real-world Clinical Setting in China [NCT04180813]85 participants (Actual)Observational2020-03-04Terminated(stopped due to Study enrollment did not meet expectation.)
Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents [NCT04287387]Phase 4180 participants (Anticipated)Interventional2020-03-02Not yet recruiting
Randomized, Non-blinded, 3-fold Crossover Study to Investigate the Bioequivalence Between Glucobay ODT Taken Without and With Water and the Glucobay Standard Tablet Following Single Oral Dosing in Healthy Male Subjects [NCT01388153]Phase 133 participants (Actual)Interventional2011-06-30Completed
Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease [NCT01863147]Phase 466 participants (Actual)Interventional2013-07-31Completed
[NCT00551954]Phase 30 participants Interventional2006-07-31Completed
A Pilot Study of the Immunomodulatory Agent Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) [NCT05487859]Phase 224 participants (Anticipated)Interventional2023-11-01Not yet recruiting
Metformin vs. Acarbose Treatment in Infertile Overweight Women With PCOS: A Prospective Randomized Clinical Trial [NCT01279512]Phase 450 participants (Actual)Interventional2006-12-31Completed
Early Diabetes Intervention Program [NCT01470937]Phase 4219 participants (Actual)Interventional1998-02-28Completed
Phase IV Study on Predictive Markers for the Effectiveness of Nateglinide or Acarbose for Controlling Post-Prandial Glucose in Type 2 Diabetics Already on Optimized Insulin Glargine Therapy [NCT00437918]Phase 485 participants (Actual)Interventional2007-01-31Completed
Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination With an α-Glucosidase Inhibitor in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glyce [NCT01242202]Phase 3113 participants (Actual)Interventional2010-10-21Completed
Effect of Exercise Training - Alone or in Combination With Acarbose - on Clinical and Metabolic Factors, and Studies of Cellular and Moleculargenetic Factors, in Type 2 Diabetes. [NCT01244971]Phase 462 participants (Actual)Interventional2004-01-31Completed
[NCT01245166]Phase 3220 participants (Anticipated)Interventional2010-11-30Recruiting
Combined Use of a Basal Insulin and Glucobay For Reducing PPG to End Diabetes Progress [NCT01248481]539 participants (Actual)Observational2010-09-30Completed
A Randomized Comparative Clinical Study on Suppression of Progression From Early Diabetes, Diet/Exercise Standard Intervention vs. Concurrent Pharmacological Standard Intervention [NCT00464594]2,560 participants Interventional2007-04-30Recruiting
A Phase III, Double-Blind, Randomized, Active Controlled, Monotherapy Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus [NCT01514838]Phase 346 participants (Actual)Interventional2012-04-23Terminated(stopped due to Discontinued due to company's strategic reason)
Randomized, Non-blinded, 3-fold Crossover Study to Investigate the Bioequivalence Between Glucobay ODT 100 mg Taken Without and With Water and the Glucobay Standard Tablet 100 mg Following Single Oral Dosing in Healthy Male Subjects [NCT01554631]Phase 134 participants (Actual)Interventional2012-03-31Completed
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]Phase 310,251 participants (Actual)Interventional1999-09-30Completed
A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy and Safety of Dapagliflozin as Monotherapy Compared With Acarbose in Drug-Naive Patients With Type 2 Diabetes Mellitus (T2DM) in China [NCT03344341]Phase 4304 participants (Actual)Interventional2017-12-15Terminated(stopped due to Study overall progress behind of scheduled timeline. Study was terminated early due to company decision.)
The Use of Incretin-based Drugs and the Risk of Pancreatic Cancer in Patients With Type 2 Diabetes [NCT02475499]886,172 participants (Actual)Observational2014-03-31Completed
Phase 4 Study Evaluation of the Effects of Acarbose Versus Glibenclamide on Mean Amplitude of Glycemic Excursions and Oxidative Stress in Patients With Type 2 Diabetes Insufficiently Controlled by Metformin [NCT00417729]Phase 451 participants (Actual)Interventional2007-01-31Completed
[NCT00417950]30 participants Interventional2007-01-31Recruiting
A Comparison of Four Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetic Patients and the Effect of Add-On Acarbose on Glycaemic Excursions During Ramadan Fasting [NCT01624116]161 participants (Actual)Interventional2011-08-31Completed
Non-inferiority Between Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. ACARB-GDM Study. [NCT03380546]Phase 3341 participants (Actual)Interventional2018-07-04Active, not recruiting
An Open-label, Randomized , Phase 4 Study to Compare the Different Efficacies of α-glucosidase Inhibitor and Sulfonylurea on Improvement of Intestinal Microbiome and Serum Incretins in Patients With Type 2 Diabetes [NCT01758471]Phase 4160 participants (Anticipated)Interventional2012-12-31Recruiting
Evaluation of Quercetin in Type 2 Diabetes: Impact on Glucose Tolerance and Postprandial Endothelial Function. [NCT01839344]Phase 219 participants (Actual)Interventional2013-05-31Completed
The Role of Salivary Contents in Taste Perception of Starch and Its Hydrolysis Products [NCT02589353]Phase 4157 participants (Actual)Interventional2017-04-21Completed
The Efficacy and Tolerability of Acarbose in Healthy Individuals: A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption. [NCT05542849]Phase 415 participants (Actual)Interventional2022-08-10Completed
Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients [NCT02355509]Phase 421 participants (Actual)Interventional2010-01-31Completed
Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study [NCT02999841]Phase 4100 participants (Anticipated)Interventional2016-03-31Recruiting
A Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Acarbose Added on Top of Metformin and Sitagliptin Combination Treatment in Type 2 Diabetes Mellitus Patients [NCT01490918]Phase 4165 participants (Actual)Interventional2012-04-30Completed
Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT): A Randomized Controlled Pilot Trial [NCT01181674]Phase 483 participants (Actual)Interventional2011-01-31Completed
Prospecitve, Non Interventional, Non Controlled, Post Marketing Survelliance Study to Evaluate Efficacy, Safety, Tolerability of Glucobay on Top of Metformin Under Daily Life Treatment Conditions [NCT01612741]19,509 participants (Actual)Observational2008-04-30Completed
Prospecitve, Non Interventional, Non Controlled, Post Marketing Survelliance Study to Evaluate Efficacy, Safety, Tolerability of Glucobay on Top of Sulfonylurea Under Daily Life Treatment Conditions [NCT01613105]4,564 participants (Actual)Observational2008-04-30Completed
A Randomized, Open-label, Non-inferiority Study to Compare the Efficacy and Safety of Voglibose and Acarbose in Patients With Type 2 Diabetes Mellitus With Poor Control of Metformin [NCT02049814]Phase 4494 participants (Actual)Interventional2014-05-09Completed
Randomized, Non-blinded Crossover Study to Establish the Bioequivalence Between Fixed Dose Combination (FDC) and Loose Combination of Acarbose and Metformin and to Investigate the Potential for a Drug-drug Interaction Following Single Oral Dosing in Healt [NCT01728740]Phase 140 participants (Actual)Interventional2012-09-30Completed
A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Ty [NCT01709305]Phase 45,570 participants (Actual)Interventional2012-11-08Completed
Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose [NCT05035849]60 participants (Actual)Interventional2020-01-30Completed
SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With Type 2 [NCT02243176]Phase 4689 participants (Actual)Interventional2014-09-30Completed
Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes [NCT02315495]Phase 322 participants (Actual)Interventional2015-04-03Completed
Lean Efficacy Phase IIa Proof of Concept Trial (LEAAP). A Study in Overweight and Obese Patients During Twenty-six Weeks, Investigating the Effect of EMP16-02 on Body Weight, Safety and Clinical Biomarkers [NCT04521751]Phase 1/Phase 2156 participants (Actual)Interventional2020-05-07Completed
An Individualized treatMent aPproach for oldER patIents: A Randomized, Controlled stUdy in Type 2 Diabetes Mellitus (IMPERIUM) [NCT02072096]Phase 4192 participants (Actual)Interventional2014-02-28Terminated(stopped due to The trial was terminated per protocol because of lack of feasibility.)
A 26-Week, Multi-Center, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-Term Intensive Insulin Therapy: Basal Insulin Based Treatment (With Prandial O [NCT03359837]Phase 4384 participants (Actual)Interventional2018-01-20Completed
The Role of Glucagon-like Peptide-1 Receptor Signalling in the Glucose-lowering Effect of Increased Carbohydrate Content in the Distal Small Intestines After Meal Ingestion in Patients With Type 2 Diabetes [NCT03241303]15 participants (Actual)Interventional2017-08-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00000620 (6) [back to overview]First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]Stroke in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00846521 (2) [back to overview]Mean Percentage of Glucose Values ≥ 140 mg/dl Over 72 Hours of Glucose Readings Measured With a Continuous Glucose Monitor
NCT00846521 (2) [back to overview]Mean Percentage of Glucose Values ≥ 140 mg/dl Over 72 Hours of Glucose Readings Measured With a Continuous Glucose Monitor
NCT00928889 (10) [back to overview]Change From Baseline in Glycosylated Serum Albumin (GSA) at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Peak Postprandial Glucose at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Postprandial Glucose Area Under the Curve at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Free Fatty Acids (FFA) at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Total Cholesterol at the End of the Study (Week 4)
NCT00928889 (10) [back to overview]Change From Baseline in Triglycerides at the End of the Study (Week 4)
NCT01030952 (15) [back to overview]The Percent of 24 Hour Hypoglycemic Measurements
NCT01030952 (15) [back to overview]Change in Percent of 24 Hour Hyperglycemic Measurements
NCT01030952 (15) [back to overview]Change in Standard Deviation (SD) From Baseline of Mean Blood Glucose (MBG) Over 24 Hours.
NCT01030952 (15) [back to overview]Changes in 24 Hour Glucose Area Under Curve (AUCpp)
NCT01030952 (15) [back to overview]Change in Mean Blood Glucose (MBG)
NCT01030952 (15) [back to overview]Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study
NCT01030952 (15) [back to overview]Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
NCT01030952 (15) [back to overview]Change in Insulin Levels (μU/ml) During Standardized Meal Test at Endpoint From Baseline
NCT01030952 (15) [back to overview]Change in Triglyceride (TG)Levels in Blood Lipid Levels During Standardized Meal Test at Endpoint
NCT01030952 (15) [back to overview]Change of Total Cholesterol in Blood Lipids Levels During Standardized Meal Test at Endpoint From Baseline at Each Time Point
NCT01030952 (15) [back to overview]Change in Mean Amplitude of Glycaemic Excursion (MAGE)
NCT01030952 (15) [back to overview]Change in Incremental Glucose Peak (IGP) From Baseline
NCT01030952 (15) [back to overview]Change in Glycated Serum Albumin (GSA) Levels From Baseline After Treatment
NCT01030952 (15) [back to overview]Change in Area Under Curve of 0-4 Hours Postprandial Glucose (AUCpp0-4hours) in Standardized Meal Test Using Continuous Glucose Monitoring System (CGMS)
NCT01030952 (15) [back to overview]Change in Mean of Daily Difference of Paired Blood Glucose Value (MODD)
NCT01177384 (4) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
NCT01177384 (4) [back to overview]Change From Baseline in Hemoglobin A1c (A1C) at Week 24
NCT01177384 (4) [back to overview]Number of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01177384 (4) [back to overview]Number of Participants Who Experienced at Least One Adverse Event
NCT01181674 (12) [back to overview]Number of Participants With Severe Hypoglycemic Episodes
NCT01181674 (12) [back to overview]Number of Participants With Symptomatic Hypoglycemic Episodes
NCT01181674 (12) [back to overview]Percentage of Participants With Normal Fasting Plasma Glucose
NCT01181674 (12) [back to overview]1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.
NCT01181674 (12) [back to overview]1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.
NCT01181674 (12) [back to overview]1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.
NCT01181674 (12) [back to overview]Change in Weight From Baseline
NCT01181674 (12) [back to overview]HbA1C
NCT01181674 (12) [back to overview]Normoglycemia on Therapy
NCT01181674 (12) [back to overview]Normoglycemia on Therapy
NCT01181674 (12) [back to overview]Normoglycemia on Therapy
NCT01181674 (12) [back to overview]Change in Fasting Plasma Glucose From Baseline
NCT01490918 (11) [back to overview]Changes in Insulin During Mixed Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),
NCT01490918 (11) [back to overview]Change in Active GLP-1 at 0 Minute During Mixed Meal Test Between 2 Groups (Group 1, group2)
NCT01490918 (11) [back to overview]Change in Active GLP-1 at 120 Minute During Mixed Meal Test Between 2 Groups (Group 1, group2)
NCT01490918 (11) [back to overview]Changes in Glucagon During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),
NCT01490918 (11) [back to overview]Changes in Glucose During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),
NCT01490918 (11) [back to overview]The Change of PPG2hr From Baseline to 24 Weeks of Treatment
NCT01490918 (11) [back to overview]Changes in MAGE of Glucose During CGMS Between 2 Group(Group 1 vs Group 2),
NCT01490918 (11) [back to overview]Changes in Mean Glucose During CGMS Between 3 Group
NCT01490918 (11) [back to overview]Changes in Variation of Glucose During CGMS Between 3 Group
NCT01490918 (11) [back to overview]The Change of Glycated Hemoglogin(HbA1c) From Baseline to 16 Weeks of Treatment
NCT01490918 (11) [back to overview]The Change of HbA1c From Baseline to 24 Weeks of Treatment
NCT01709305 (7) [back to overview]Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)
NCT01709305 (7) [back to overview]Percentage of Participants With a GI AE of Diarrhea (Phase 2)
NCT01709305 (7) [back to overview]Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)
NCT01709305 (7) [back to overview]Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)
NCT01709305 (7) [back to overview]Percentage of Participants With a GI AE of Abdominal Pain (Phase 2)
NCT01709305 (7) [back to overview]Percentage of Participants With a GI AE of Vomiting (Phase 2)
NCT01709305 (7) [back to overview]Percentage of Participants With Hypoglycemia Events (Phase 2)
NCT02049814 (11) [back to overview]Change From Baseline in Body Weight Over Time
NCT02049814 (11) [back to overview]Change From Baseline in Fasting Blood Glucose Over Time
NCT02049814 (11) [back to overview]Change From Baseline in Postprandial Plasma Glucose (PPG) Over Time
NCT02049814 (11) [back to overview]Change From Baseline in Postprandial Serum Glucagon at Week 12
NCT02049814 (11) [back to overview]Change From Baseline in Insulin Homeostatic Model Assessment Beta Cell Function (HOMA β) at Week 12
NCT02049814 (11) [back to overview]Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance (HOMA IR) at Week 12
NCT02049814 (11) [back to overview]Change From Baseline in Fasting Glucagon at Week 12
NCT02049814 (11) [back to overview]Change From Baseline in Fasting Insulin at Week 12
NCT02049814 (11) [back to overview]Change From Baseline in Postprandial Serum Insulin at Week 12
NCT02049814 (11) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
NCT02049814 (11) [back to overview]Change From Baseline in HbA1c at Week 6
NCT02072096 (6) [back to overview]Number of Participants With Total Hypoglycemia and Other Categories of Hypoglycemia
NCT02072096 (6) [back to overview]Change From Baseline in Body Mass Index (BMI)
NCT02072096 (6) [back to overview]Change From Baseline of Estimated Glomerular Filtration Rate (eGFR)
NCT02072096 (6) [back to overview]Change From Baseline of Urinary Albumin to Creatinine Ratio
NCT02072096 (6) [back to overview]Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia
NCT02072096 (6) [back to overview]Percentage of Participants Requiring Alternative Treatment Due to Glycemic Failure of First Line Injectable Therapy
NCT02243176 (9) [back to overview]Absolute Change From Baseline in HbA1c at Week 24 (DAO)
NCT02243176 (9) [back to overview]Absolute Change From Baseline in HbA1c at Week 24 (DAO)
NCT02243176 (9) [back to overview]Change From Baseline in 2H Postprandial Glucose (2HPPG)
NCT02243176 (9) [back to overview]Change From Baseline in HOMA-β
NCT02243176 (9) [back to overview]Proportion (%) of Patients Achieving a Therapeutic Glycemic Response Defined as HbA1c<7.0%
NCT02243176 (9) [back to overview]Proportion (%) of Patients Achieving HbA1c<7.0% Without GI Adverse Events
NCT02243176 (9) [back to overview]Proportion (%) of Patients With Any GI Adverse Events
NCT02243176 (9) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG)
NCT02243176 (9) [back to overview]Change From Baseline in Body Weight
NCT02865499 (1) [back to overview]Change in Microbiome

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate641
Lipid Trial: Placebo667

[back to top]

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control391
Glycemia Trial: Standard Control327

[back to top]

Stroke in the Blood Pressure Trial.

Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control36
BP Trial: Standard Control62

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate291
Lipid Trial: Placebo310

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control208
BP Trial: Standard Control237

[back to top]

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control503
Glycemia Trial: Standard Control543

[back to top]

Mean Percentage of Glucose Values ≥ 140 mg/dl Over 72 Hours of Glucose Readings Measured With a Continuous Glucose Monitor

(NCT00846521)
Timeframe: After 6 Weeks (post treatment)

Interventionpercentage of glucose excursions ≥ 140 (Mean)
Acarbose Administration2

[back to top]

Mean Percentage of Glucose Values ≥ 140 mg/dl Over 72 Hours of Glucose Readings Measured With a Continuous Glucose Monitor

(NCT00846521)
Timeframe: At baseline (before treatment)

Interventionpercentage of glucose excursions ≥ 140 (Mean)
Acarbose Administration8

[back to top]

Change From Baseline in Glycosylated Serum Albumin (GSA) at the End of the Study (Week 4)

Blood samples were collected for measurement of GSA prior to (fasting) the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. GSA was assayed at a central laboratory. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

InterventionPercentage (Mean)
Nateglinide 120 mg-1.2
Acarbose 50 mg-1.2

[back to top]

Change From Baseline in Peak Postprandial Glucose at the End of the Study (Week 4)

Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The peak postprandial glucose values were used in the calculation of change from Baseline at Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

Interventionmmol/L (Mean)
Nateglinide 120 mg-2.350
Acarbose 50 mg-3.129

[back to top]

Change From Baseline in Postprandial Glucose Area Under the Curve at the End of the Study (Week 4)

Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The postprandial glucose area under the curve was calculated using values from the 4 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

Interventionmmol*min/L (Mean)
Nateglinide 120 mg-217.628
Acarbose 50 mg-278.447

[back to top]

Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4)

Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. PPGE was defined as the mean difference between the preprandial glucose value and the postprandial glucose value measured at 2 hours in a standardized meal test. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

Interventionmmol/L (Mean)
Nateglinide 120 mg-1.775
Acarbose 50 mg-2.434

[back to top]

Change From Baseline in Free Fatty Acids (FFA) at the End of the Study (Week 4)

Blood samples were collected for measurement of FFA prior to (fasting) and 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. FFA was assayed at a central laboratory. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

,
Interventionmmol/L (Mean)
Fasting, N=73, 7530 minutes, N=73, 7560 minutes, N=72, 7590 minutes, N=72, 75120 minutes, N=73, 75
Acarbose 50 mg-0.040-0.048-0.048-0.042-0.034
Nateglinide 120 mg-0.048-0.112-0.224-0.109-0.099

[back to top]

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study (Week 4)

Blood samples were collected for measurement of HDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. HDL-C was assessed at each study site using the same method and same reference value. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

,
Interventionmmol/L (Mean)
Fasting, N=74, 77120 minutes, N=74, 76
Acarbose 50 mg-0.0390.003
Nateglinide 120 mg0.0200.023

[back to top]

Change From Baseline in High-sensitivity C-reactive Protein (hsCRP) at the End of the Study (Week 4)

Blood samples were collected for measurement of hsCRP prior to (fasting) and 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. hsCRP was assayed at a central laboratory. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

,
Interventionmg/dL (Mean)
Fasting, N=73, 7530 minutes, N=73, 7560 minutes, N=72, 7590 minutes, N=72, 75120 minutes, N=72, 74
Acarbose 50 mg0.0800.0240.0710.0770.074
Nateglinide 120 mg-0.229-0.227-0.219-0.220-0.218

[back to top]

Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the End of the Study (Week 4)

Blood samples were collected for measurement of LDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. LDL-C was assessed at each study site using the same method and same reference value. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

,
Interventionmmol/L (Mean)
Fasting, N=74, 77120 minutes, N=74, 76
Acarbose 50 mg0.0360.044
Nateglinide 120 mg0.036-0.000

[back to top]

Change From Baseline in Total Cholesterol at the End of the Study (Week 4)

Blood samples were collected for measurement of total cholesterol prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. Total cholesterol was assessed at each study site using the same method and same reference value. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

,
Interventionmmol/L (Mean)
Fasting, N=74, 77120 minutes, N=74, 76
Acarbose 50 mg-0.149-0.059
Nateglinide 120 mg0.0150.010

[back to top]

Change From Baseline in Triglycerides at the End of the Study (Week 4)

Blood samples were collected for measurement of triglycerides prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 4. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. Triglycerides were assessed at each study site using the same method and same reference value. (NCT00928889)
Timeframe: Baseline to the end of the study (Week 4)

,
Interventionmmol/L (Mean)
Fasting, N=74, 77120 minutes, N=74, 76
Acarbose 50 mg-0.418-0.396
Nateglinide 120 mg-0.0100.026

[back to top]

The Percent of 24 Hour Hypoglycemic Measurements

Measures/compares changes in percentage of hypoglycemia(<3.9mmol/l or <70 mg/dl) in glucose measurements in 24hours by continuous glucose monitoring system (CGMS) at endpoint from baseline between groups. Reported values are percent change of the base absolute values [100% * ((X-Y)/Y)] (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionpercent of measurements (Mean)
Nateglinide0.82
Acarbose-0.57

[back to top]

Change in Percent of 24 Hour Hyperglycemic Measurements

Measures/compares changes in percentage of hyperglycemia (>7.8mmol/l or 140 mg/dl) in glucose measurements in 24 hours by continuous glucose monitoring system (CGMS) at endpoint from baseline between groups. Reported values are percent change of the base absolute values [100% * ((X-Y)/Y)] (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionpercent of measurements (Mean)
Nateglinide-50.83
Acarbose-33.82

[back to top]

Change in Standard Deviation (SD) From Baseline of Mean Blood Glucose (MBG) Over 24 Hours.

Change in standard deviation (SD) from baseline of mean blood glucose (MBG) describes the range of blood glucose fluctuation over 24 hours. (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionmmol/l (Mean)
Nateglinide-0.48
Acarbose-0.63

[back to top]

Changes in 24 Hour Glucose Area Under Curve (AUCpp)

Blood samples were collected for measurement of plasma glucose at 30, 60, 90, and 120 minutes following the start of a standardized meal test at Baseline and Week 4. The postprandial glucose area under the curve was calculated using values from the 4 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. (NCT01030952)
Timeframe: baseline, end of study (3 weeks)

Interventionmmol*min/L (Mean)
Nateglinide-1.16
Acarbose-0.78

[back to top]

Change in Mean Blood Glucose (MBG)

The 24 hour mean blood glucose (MBG) level was calculated as the mean of all the consecutive readings on baseline and end of study(3 weeks later) separately. (NCT01030952)
Timeframe: baseline and at 3 weeks (end of study)

Interventionmillimoles per litre (mmol/l) (Mean)
Nateglinide-1.16
Acarbose-0.78

[back to top]

Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the End of the Study

Blood samples were collected for measurement of HDL-C prior to (fasting) and 120 minutes following the start of a standardized meal test at Baseline and Week 3. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM. HDL-C was assessed at each study site using the same method and same reference value. (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

,
Interventionmillimoles per litre (mmol/l) (Mean)
0 minutes30 minutes120 minutes
Acarbose-0.020.010.00
Nateglinide0.200.020.03

[back to top]

Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

change in LDL-C at 0, 30 and 120 minutes (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

,
Interventionmillimoles per litre (mmol/l) (Mean)
0 minutes30 minutes120 minutes
Acarbose0.0640.090.13
Nateglinide-0.04-0.06-0.04

[back to top]

Change in Insulin Levels (μU/ml) During Standardized Meal Test at Endpoint From Baseline

This outcome measure calculated the change in insulin levels between groups over time at 0, 30 then 120 minutes (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

,
Intervention(μU/ml) (Mean)
0 minutes30 minutes120 minutes
Acarbose-0.21-6.64-16.24
Nateglinide0.3213.8715.03

[back to top]

Change in Triglyceride (TG)Levels in Blood Lipid Levels During Standardized Meal Test at Endpoint

TG change in blood lipids level from baseline to endpoint (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

,
Interventionmillimoles per litre (mmol/l) (Mean)
0 minutes30 minutes120 minutes
Acarbose-0.48-0.39-0.47
Nateglinide-0.19-0.23-0.19

[back to top]

Change of Total Cholesterol in Blood Lipids Levels During Standardized Meal Test at Endpoint From Baseline at Each Time Point

time to change in Total Cholesterol blood lipids level at 0, 30, 120 minutes (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

,
Interventionmillimoles per litre (mmol/l) (Mean)
0 minutes30 minutes120 minutes
Acarbose-0.090.560.03
Nateglinide-0.03-0.06-0.01

[back to top]

Change in Mean Amplitude of Glycaemic Excursion (MAGE)

mean amplitude of glycaemic excursion (MAGE) is an average of the amplitudes of all glycemic excursions greater than a prespecified threshold size (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionmmol/l (Mean)
Nateglinide5.27
Acarbose5.03

[back to top]

Change in Incremental Glucose Peak (IGP) From Baseline

Incremental glucose peak (IGP) was the maximal incremental increase in blood glucose obtained at any point after meal (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionmillimoles per litre (mmol/L) (Mean)
Nateglinide-2.72
Acarbose-1.89

[back to top]

Change in Glycated Serum Albumin (GSA) Levels From Baseline After Treatment

GSA levels were to be determined by CGMS at 7:00~10:00 am in the 4-hour standardized meal test before treatment after overnight fasting for efficacy assessments (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionpercent (Mean)
Nateglinide-2.22
Acarbose-1.74

[back to top]

Change in Area Under Curve of 0-4 Hours Postprandial Glucose (AUCpp0-4hours) in Standardized Meal Test Using Continuous Glucose Monitoring System (CGMS)

"The postprandial glucose area under the curve (AUC)was calculated using values from the 3 time points. Participants were fasting (no calorie intake for at least 8 hours prior to the meal test) and completed the standardized meal test between 7 and 10 AM.~0-4 hours AUC were calculated using trapezoid methods." (NCT01030952)
Timeframe: 3 weeks (end of study) minus baseline

Interventionmillimoles hours per litre (mmol*hr/L) (Least Squares Mean)
Nateglinide-9.20
Acarbose-9.92

[back to top]

Change in Mean of Daily Difference of Paired Blood Glucose Value (MODD)

The mean of the daily differences (MODD), calculated as the average absolute difference of paired glucose values during two successive 24 hour periods, was used to assess day-to-day glycaemic variability. (NCT01030952)
Timeframe: baseline, 3 weeks (end of study)

Interventionmillimoles per litre (mmol/l) (Mean)
Nateglinide-0.06
Acarbose-0.21

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG. Efficacy analyses treated data as missing after the initiation of rescue therapy. (NCT01177384)
Timeframe: Baseline and Week 24

Interventionmg/dL (Least Squares Mean)
Sitagliptin-17.9
Placebo-3.5

[back to top]

Change From Baseline in Hemoglobin A1c (A1C) at Week 24

A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. Efficacy analyses treated data as missing after the initiation of rescue therapy. (NCT01177384)
Timeframe: Baseline and Week 24

InterventionPercent (Least Squares Mean)
Sitagliptin-0.76
Placebo-0.14

[back to top]

Number of Participants Who Discontinued Study Drug Due to an Adverse Event

(NCT01177384)
Timeframe: Up to 24 Weeks

InterventionParticipants (Number)
Sitagliptin5
Placebo2

[back to top]

Number of Participants Who Experienced at Least One Adverse Event

(NCT01177384)
Timeframe: Up to Week 24 + 14 Day Post-Study Follow-up

InterventionParticipants (Number)
Sitagliptin62
Placebo58

[back to top]

Number of Participants With Severe Hypoglycemic Episodes

(NCT01181674)
Timeframe: 52 weeks

InterventionParticipants (Count of Participants)
Group 1 (Short)0
Group 2 (Long)0
Standard Care0

[back to top]

Number of Participants With Symptomatic Hypoglycemic Episodes

(NCT01181674)
Timeframe: 52 weeks

InterventionParticipants (Count of Participants)
Group 1 (Short)9
Group 2 (Long)10
Standard Care1

[back to top]

Percentage of Participants With Normal Fasting Plasma Glucose

Normal fasting plasma glucose is defined as <6.1 mmol/L. (NCT01181674)
Timeframe: 52 weeks

InterventionParticipants (Count of Participants)
Group 1 (Short)5
Group 2 (Long)5
Standard Care3

[back to top]

1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.

Normal glucose tolerance is defined as a fasting plasma glucose <6.1 mmol/L and a 2-hour pc plasma glucose <7.8 mmol/L on a 75 g oral glucose tolerance test off diabetes drugs. (NCT01181674)
Timeframe: (1) 20 weeks and (2) 28 weeks

InterventionParticipants (Count of Participants)
Group 1 and Standard care at 20 weeks
Group 1 (Short)2

[back to top]

1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.

Normal glucose tolerance is defined as a fasting plasma glucose <6.1 mmol/L and a 2-hour pc plasma glucose <7.8 mmol/L on a 75 g oral glucose tolerance test off diabetes drugs. (NCT01181674)
Timeframe: (1) 20 weeks and (2) 28 weeks

InterventionParticipants (Count of Participants)
Group 2 and Standard care at 28 weeks
Group 2 (Long)2

[back to top]

1) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 1 Compared to the Control Group. 2) Percentage of Participants With Normal Glucose Tolerance in the Experimental Group 2 Compared to the Control Group.

Normal glucose tolerance is defined as a fasting plasma glucose <6.1 mmol/L and a 2-hour pc plasma glucose <7.8 mmol/L on a 75 g oral glucose tolerance test off diabetes drugs. (NCT01181674)
Timeframe: (1) 20 weeks and (2) 28 weeks

InterventionParticipants (Count of Participants)
Group 1 and Standard care at 20 weeksGroup 2 and Standard care at 28 weeks
Standard Care21

[back to top]

Change in Weight From Baseline

(NCT01181674)
Timeframe: Baseline, 8, 20, 28 and 52 weeks

,,
Interventionkg (Mean)
Baseline8 weeks20 weeks28 weeks52 weeks
Group 1 (Short)99.595.392.893.396.6
Group 2 (Long)95.392.490.591.793.8
Standard Care89.387.186.386.186.5

[back to top]

HbA1C

(NCT01181674)
Timeframe: 8, 20, 28 and 52 weeks

,,
Interventionpercent (Mean)
8 weeks20 weeks28 weeks52 weeks
Group 1 (Short)6.16.26.56.4
Group 2 (Long)6.06.16.46.7
Standard Care6.66.66.66.5

[back to top]

Normoglycemia on Therapy

"Percentage of participants achieving normoglycemia on therapy in the experimental group 1 compared to the control group.~Percentage of participants achieving normoglycemia on therapy in the experimental group 2 compared to the control group.~Normoglycemia on therapy is defined as a mean fasting capillary blood glucose NCT01181674)
Timeframe: (1) 8 weeks and (2) 16 weeks

InterventionParticipants (Count of Participants)
Group 2 and Standard care at 16 weeks
Group 2 (Long)19

[back to top]

Normoglycemia on Therapy

"Percentage of participants achieving normoglycemia on therapy in the experimental group 1 compared to the control group.~Percentage of participants achieving normoglycemia on therapy in the experimental group 2 compared to the control group.~Normoglycemia on therapy is defined as a mean fasting capillary blood glucose NCT01181674)
Timeframe: (1) 8 weeks and (2) 16 weeks

InterventionParticipants (Count of Participants)
Group 1 and Standard care at 8 weeksGroup 2 and Standard care at 16 weeks
Standard Care11

[back to top]

Normoglycemia on Therapy

"Percentage of participants achieving normoglycemia on therapy in the experimental group 1 compared to the control group.~Percentage of participants achieving normoglycemia on therapy in the experimental group 2 compared to the control group.~Normoglycemia on therapy is defined as a mean fasting capillary blood glucose NCT01181674)
Timeframe: (1) 8 weeks and (2) 16 weeks

InterventionParticipants (Count of Participants)
Group 1 and Standard care at 8 weeks
Group 1 (Short)14

[back to top]

Change in Fasting Plasma Glucose From Baseline

(NCT01181674)
Timeframe: Baseline and 52 weeks

Interventionmmol/L (Mean)
Group 1 (Short)-0.23
Group 2 (Long)-0.64
Standard Care0.05

[back to top]

Changes in Insulin During Mixed Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),

Change of AUC(area under the curve) of insulin at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin) (NCT01490918)
Timeframe: Visit 2(baseline) and Visit 5(16W)

Interventionpg min/mL (Mean)
Placebo+Metformin+Sitagliptin647.65
Sitagliptin+Metformin+Acarbose221.42

[back to top]

Change in Active GLP-1 at 0 Minute During Mixed Meal Test Between 2 Groups (Group 1, group2)

Change of active GLP-1 at 0 minute during mixed meal test at 16 week from baseline between 2 groups(group1, group2) (NCT01490918)
Timeframe: baseline, 16 week

Interventionpg/ml (Mean)
Placebo+Metformin+Sitagliptin-8.55
Sitagliptin+Metformin+Acarbose-9.33

[back to top]

Change in Active GLP-1 at 120 Minute During Mixed Meal Test Between 2 Groups (Group 1, group2)

Change of active GLP-1 at 120 minute during mixed meal test at 16 week from baseline between 2 groups(group1, group2) (NCT01490918)
Timeframe: baseline, 16 week

Interventionpg/ml (Mean)
Placebo+Metformin+Sitagliptin-32.92
Sitagliptin+Metformin+Acarbose-23.36

[back to top]

Changes in Glucagon During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),

Change of AUC(area under the curve) of glucagon at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin) (NCT01490918)
Timeframe: Visit 2(baseline) and Visit 5(16W)

Interventionmin pg/mL (Mean)
Placebo+Metformin+Sitagliptin-79.22
Sitagliptin+Metformin+Acarbose-1411.79

[back to top]

Changes in Glucose During Meal Tolerance Test Between 2 Group(Group 1 vs Group 2),

Change of AUC(area under the curve) of glucose at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin) (NCT01490918)
Timeframe: Visit 2(baseline) and Visit 5(16W)

Interventionmg min/dL (Mean)
Placebo+Metformin+Sitagliptin28.85
Sitagliptin+Metformin+Acarbose-743.08

[back to top]

The Change of PPG2hr From Baseline to 24 Weeks of Treatment

The change of PPG2hr (post prandia blood glucose 2hr from baseline to 24 weeks of treatment between 3 groups (NCT01490918)
Timeframe: baseline, 24 weeks

Interventionmmol/L (Mean)
Placebo+Metformin+Sitagliptin-1.73
Sitagliptin+Metformin+Acarbose-1.76
Placebo+Sitagliptin+Acarbose0.06

[back to top]

Changes in MAGE of Glucose During CGMS Between 2 Group(Group 1 vs Group 2),

Change of mean amplitude of glycemic excursion of CGMS(continuous glucose monitoring system) data at 16 week from baseline between 2 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin) (NCT01490918)
Timeframe: Visit 2(baseline) and Visit 5(16W)

Interventionmg/dL (Mean)
Placebo+Metformin+Sitagliptin-8.79
Sitagliptin+Metformin+Acarbose-18.5
Placebo + Acarbose + Sitagliptin2.72

[back to top]

Changes in Mean Glucose During CGMS Between 3 Group

Change of mean glucose of CGMS(continuous glucose monitoring system) data at 16 week from baseline between 3 groups (NCT01490918)
Timeframe: Visit 2(baseline) and Visit 5(16W)

Interventionmmol/L (Mean)
Placebo+Metformin+Sitagliptin-0.91
Sitagliptin+Metformin+Acarbose-1.16
Placebo + Sitagliptin + Acarbose3.22

[back to top]

Changes in Variation of Glucose During CGMS Between 3 Group

Change of standard deviation of CGMS(continuous glucose monitoring system) data at 16 week from baseline between 3 groups (placebo+metformin + sitagliptin vs acarbose + metformin + sitagliptin vs placebo + acarbose + sitagliptin) (NCT01490918)
Timeframe: Visit 2(baseline) and Visit 5(16W)

Interventionmmol/L (Mean)
Placebo+Metformin+Sitagliptin-0.33
Sitagliptin+Metformin+Acarbose-0.65
Placebo + Acarbose + Sitagliptin0.03

[back to top]

The Change of Glycated Hemoglogin(HbA1c) From Baseline to 16 Weeks of Treatment

The change of glycated hemoglogin(HbA1c) from baseline to 16 weeks of treatment between Placebo + Metformin+Sitagliptin and Metformin + Sitagliptin + Acarbose group (NCT01490918)
Timeframe: baseline, 16 weeks

Intervention% of HbA1c (Mean)
Placebo+Metformin+Sitagliptin-0.09
Sitagliptin+Metformin+Acarbose-0.44
Placebo+Sitagliptin+Acarbose0.84

[back to top]

The Change of HbA1c From Baseline to 24 Weeks of Treatment

The change of glycated hemoglogin(HbA1c) from baseline to 24 weeks of treatment between 3 groups (NCT01490918)
Timeframe: baseline, 24 weeks

Intervention% of HbA1c (Mean)
Placebo+Metformin+Sitagliptin-0.34
Sitagliptin+Metformin+Acarbose-0.47
Placebo+Sitagliptin+Acarbose0.23

[back to top]

Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)

HbA1c is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change from baseline reflects the Week 44 A1C minus baseline A1C. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. Change from baseline was based on the constrained longitudinal data analysis (cLDA) model including all available measurements from baseline through the last visit. The terms in the cLDA model include treatment, time in weeks (categorical), regions, and treatment-by-time interaction. (NCT01709305)
Timeframe: Phase 2 Baseline (Week 20) and Week 44

InterventionPercent (Least Squares Mean)
Phase 2: Metformin + Sitagliptin + Glimepiride-0.65
Phase 2: Metformin + Sitagliptin + Repaglinide-0.62
Phase 2: Metformin + Sitagliptin + Acarbose-0.46
Phase 2: Metformin + Sitagliptin + Gliclazide-0.69

[back to top]

Percentage of Participants With a GI AE of Diarrhea (Phase 2)

"The percentage of participants with a GI AE of diarrhea was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0.5
Phase 2: Metformin + Sitagliptin + Repaglinide0.4
Phase 2: Metformin + Sitagliptin + Acarbose0.4
Phase 2: Metformin + Sitagliptin + Gliclazide0.9

[back to top]

Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)

Change from baseline in body weight in Phase 2 was reported. Change from baseline reflects the Week 44 body weight minus baseline body weight. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. (NCT01709305)
Timeframe: Phase 2 Baseline (Week 20), Week 44

Interventionkg (Mean)
Phase 2: Metformin + Sitagliptin + Glimepiride0.4
Phase 2: Metformin + Sitagliptin + Repaglinide0.2
Phase 2: Metformin + Sitagliptin + Acarbose-0.9
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

[back to top]

Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)

"The percentage of participants with a GI AE of nausea was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0
Phase 2: Metformin + Sitagliptin + Repaglinide0
Phase 2: Metformin + Sitagliptin + Acarbose0.4
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

[back to top]

Percentage of Participants With a GI AE of Abdominal Pain (Phase 2)

"The percentage of participants with a GI AE of abdominal pain was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0
Phase 2: Metformin + Sitagliptin + Repaglinide0
Phase 2: Metformin + Sitagliptin + Acarbose0.4
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

[back to top]

Percentage of Participants With a GI AE of Vomiting (Phase 2)

"The percentage of participants with a GI AE of vomiting was reported." (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride0.2
Phase 2: Metformin + Sitagliptin + Repaglinide0
Phase 2: Metformin + Sitagliptin + Acarbose0.2
Phase 2: Metformin + Sitagliptin + Gliclazide0.2

[back to top]

Percentage of Participants With Hypoglycemia Events (Phase 2)

Hypoglycemia events represent epidsodes symptomatic of hypoglycemia (e.g., weakness, dizziness, shakiness, increased sweating, palpitations, or confusion) and/or finger stick glucose values of ≤70 mg/dL (3.9 mmol/L). The percentage of participants with hypoglycemia events was reported. (NCT01709305)
Timeframe: From Week 20 through Week 44

InterventionPercentage of Participants (Number)
Phase 2: Metformin + Sitagliptin + Glimepiride8.9
Phase 2: Metformin + Sitagliptin + Repaglinide6.1
Phase 2: Metformin + Sitagliptin + Acarbose0.5
Phase 2: Metformin + Sitagliptin + Gliclazide3.6

[back to top]

Change From Baseline in Body Weight Over Time

The change between body weight at weeks 2, 6 and 12 or relative to baseline. (NCT02049814)
Timeframe: Baseline, Weeks 2, 6 and 12

,
Interventionkg (Least Squares Mean)
Change at Week 2Change at Week 6Change at Week 12
Metformin + Acarbose 50 mg-0.1731-0.7975-1.4394
Metformin + Voglibose 0.2 mg-0.016-0.6315-1.1563

[back to top]

Change From Baseline in Fasting Blood Glucose Over Time

The change between the fasting blood glucose value collected at weeks 6 and 12 or final visit relative to baseline. (NCT02049814)
Timeframe: Baseline, Weeks 6 and 12

,
Interventionmmol/L (Least Squares Mean)
Change at Week 6Change at Week 12
Metformin + Acarbose 50 mg-0.8851-0.8029
Metformin + Voglibose 0.2 mg-0.4234-0.5041

[back to top]

Change From Baseline in Postprandial Plasma Glucose (PPG) Over Time

The change between the value of glucose after 1 and 2 hours of meal, measured by the meal tolerance test collected at Weeks 6 and 12 or relative to baseline. (NCT02049814)
Timeframe: 1 and 2 hours after meal at Baseline, Weeks 6 and 12

,
Interventionmmol/L (Least Squares Mean)
Change at Week 6 (1 hour PPG)Change at Week 12 (1 hour PPG)Change at Week 6 (2 hour PPG)Change at Week 12 (2 hour PPG)
Metformin + Acarbose 50 mg-3.8557-2.1187-4.0015-3.2347
Metformin + Voglibose 0.2 mg-2.5149-2.1187-2.7461-2.6099

[back to top]

Change From Baseline in Postprandial Serum Glucagon at Week 12

The change from Baseline in postprandial serum glucagon, after 1 and 2 hours of meal collected at Week 12 relative to baseline. (NCT02049814)
Timeframe: 1 and 2 hours after meal at Baseline and Week 12

,
Interventionpg/mL (Least Squares Mean)
Change at Week 12 (1 hour)Change at Week 12 (2 hours)
Metformin + Acarbose 50 mg15.6913.0188
Metformin + Voglibose 0.2 mg20.440934.8518

[back to top]

Change From Baseline in Insulin Homeostatic Model Assessment Beta Cell Function (HOMA β) at Week 12

The change between the value of HOMA-beta cell function collected at Week 12 and HOMA-beta cell function collected at Baseline. The homeostatic model assessment estimates steady state beta cell function as a percentage of a normal reference population (%B). HOMA %B = 20 * insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5. (NCT02049814)
Timeframe: Baseline, Week 12

InterventionPercentage beta cell function (Least Squares Mean)
Metformin + Voglibose 0.2 mg15.3149
Metformin + Acarbose 50 mg28.1739

[back to top]

Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance (HOMA IR) at Week 12

The change between the value of HOMA-IR collected at Week 12 and HOMA-IR collected at Baseline. HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (µIU/mL) * fasting plasma glucose (mmol/L) / 22.5. A higher number indicates a greater insulin resistance. (NCT02049814)
Timeframe: Baseline, Week 12

InterventionInsulin resistance (Least Squares Mean)
Metformin + Voglibose 0.2 mg-0.366
Metformin + Acarbose 50 mg0.4983

[back to top]

Change From Baseline in Fasting Glucagon at Week 12

The change between the fasting glucagon value collected at week 12 or final visit relative to baseline. (NCT02049814)
Timeframe: Baseline, Week 12

Interventionpg/mL (Least Squares Mean)
Metformin + Voglibose 0.2 mg5.7543
Metformin + Acarbose 50 mg11.4541

[back to top]

Change From Baseline in Fasting Insulin at Week 12

The change between the fasting insulin value collected at week 12 or final visit relative to baseline. (NCT02049814)
Timeframe: Baseline, Week 12

InterventionμU/dL (Least Squares Mean)
Metformin + Voglibose 0.2 mg0.0319
Metformin + Acarbose 50 mg2.4169

[back to top]

Change From Baseline in Postprandial Serum Insulin at Week 12

The change from Baseline in postprandial serum insulin, after 1 and 2 hours of meal collected at Week 12 relative to baseline. (NCT02049814)
Timeframe: 1 and 2 hours after meal at Baseline and Week 12

,
InterventionμU/dL (Least Squares Mean)
Change at Week 12 (1 hour)Change at Week 12 (2 hours)
Metformin + Acarbose 50 mg-1.44-0.1526
Metformin + Voglibose 0.2 mg-0.34353.2972

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline. (NCT02049814)
Timeframe: Baseline, Week 12

Interventionpercentage of glycated hemoglobin (Least Squares Mean)
Metformin + Voglibose 0.2 mg-0.6982
Metformin + Acarbose 50 mg-0.9335

[back to top]

Change From Baseline in HbA1c at Week 6

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 6 relative to baseline. (NCT02049814)
Timeframe: Baseline and Week 6

Interventionpercentage of glycated hemoglobin (Least Squares Mean)
Metformin + Voglibose 0.2 mg-0.4765
Metformin + Acarbose 50 mg-0.631

[back to top]

Number of Participants With Total Hypoglycemia and Other Categories of Hypoglycemia

(NCT02072096)
Timeframe: Baseline to last participant visit (up to 72 weeks)

,
InterventionParticipants (Number)
Total HypoglycemiaSevere HypoglycemiaClinically Significant HypoglycemiaSymptomatic HypoglycemiaAsymptomatic HypoglycemiaProbable Symptomatic HypoglycemiaUnspecified HypoglycemiaRelative HypoglycemiaNocturnal Hypoglycemia
Strategy A (Glucose-Dependent)1000580214
Strategy B (Reference)5001343077610

[back to top]

Change From Baseline in Body Mass Index (BMI)

(NCT02072096)
Timeframe: Baseline, Week 72

Interventionkilogram per square meter (kg/m^2) (Mean)
Strategy A (Glucose-Dependent)-0.47
Strategy B (Reference)0.20

[back to top]

Change From Baseline of Estimated Glomerular Filtration Rate (eGFR)

The eGFR is used in addition to the Urinary Albumin to Creatinine Ratio to measure the incidence and progression of diabetic kidney disease. (NCT02072096)
Timeframe: Baseline, Week 72

Interventionmilliliter per minute/1.73 square meter (Mean)
Strategy A (Glucose-Dependent)-5.00
Strategy B (Reference)-5.88

[back to top]

Change From Baseline of Urinary Albumin to Creatinine Ratio

The Urinary Albumin to Creatinine Ratio is used in addition to Estimated Glomerular Filtration Rate (eGFR) to measure the incidence and progression of diabetic kidney disease. (NCT02072096)
Timeframe: Baseline, Week 72

Interventionmilligram per millimole (mg/mmol) (Mean)
Strategy A (Glucose-Dependent)1.85
Strategy B (Reference)1.85

[back to top]

Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia

Failed to reach and maintain HbA1c target, without clinically significant hypoglycemia, is defined as having 2 consecutive HbA1c > upper limit of HbA1c target over 12 weeks starting from Week 24 for participants with HbA1c data beyond Week 24, or Week 24 HbA1c > upper limit of HbA1c target for participants without HbA1c data beyond Week 24. Clinically significant hypoglycemia is defined as any severe hypoglycemia or repeated hypoglycemia interrupting participants activities or sleep and associated with blood glucose ≤3.9 millimole per liter (mmol/L), or repeated asymptomatic hypoglycemia associated with blood glucose <3.0 mmol/L. Success is defined as lacking of failure. (NCT02072096)
Timeframe: Baseline to last participant visit (up to 72 weeks)

Interventionpercentage of participants (Number)
Strategy A (Glucose-Dependent)64.5
Strategy B (Reference)54.9

[back to top]

Percentage of Participants Requiring Alternative Treatment Due to Glycemic Failure of First Line Injectable Therapy

(NCT02072096)
Timeframe: Baseline to last participant visit (up to 72 weeks)

Interventionpercentage of participants (Number)
Strategy A (Glucose-Dependent)21
Strategy B (Reference)13

[back to top]

Absolute Change From Baseline in HbA1c at Week 24 (DAO)

Primary Objective: Efficacy of saxagliptin plus metformin on glycemic control compared with acarbose plus metformin in patients with T2D inadequately controlled with metformin. By Measure absolute change from baseline in HbA1c at Week 24 (NCT02243176)
Timeframe: From baseline to 24 week

Intervention% (HbA1c) (Least Squares Mean)
Saxagliptin-0.82
Acarbose-0.78

[back to top]

Absolute Change From Baseline in HbA1c at Week 24 (DAO)

The primary endpoint was analyzed based on Per protocol analysis set as the supportive analysis. (NCT02243176)
Timeframe: From baseline to 24 week

Intervention% (HbA1c) (Least Squares Mean)
Saxagliptin-0.83
Acarbose-0.80

[back to top]

Change From Baseline in 2H Postprandial Glucose (2HPPG)

Secondary objective: Effects of saxagliptin versus acarbose on the additional parameters, by measure change from baseline in fasting plasma glucose, 2h postprandial glucose, β-cell function, body weight at week 24 (NCT02243176)
Timeframe: From baseline to 24 week

Interventionmmol/l (Least Squares Mean)
Saxagliptin-0.77
Acarbose-1.07

[back to top]

Change From Baseline in HOMA-β

Secondary objective: Effects of saxagliptin versus acarbose on the additional parameters, by measure change from baseline in fasting plasma glucose, 2h postprandial glucose, β-cell function was estimated by the Homeostasis model assessment-β (HOMA-β), which was defined as fasting insulin (mU/mL) x 20 / (fasting glucose (mmol/mL) - 3.5, body weight at week 24 (NCT02243176)
Timeframe: From baseline to 24 week

InterventionmU/mmol (Least Squares Mean)
Saxagliptin20.56
Acarbose13.08

[back to top]

Proportion (%) of Patients Achieving a Therapeutic Glycemic Response Defined as HbA1c<7.0%

Secondary Objective: Effects of saxagliptin versus acarbose on the additional parameters, by measure proportion (%) of patients achieving a therapeutic glycemic response defined as HbA1c<7.0% (NCT02243176)
Timeframe: 24 weeks

Interventionpercentage of participants (Number)
Saxagliptin38.3
Acarbose41.5

[back to top]

Proportion (%) of Patients Achieving HbA1c<7.0% Without GI Adverse Events

Secondary Objective: Assessment of any gastrointestinal adverse events of saxagliptin versus acarbose. by measure proportion (%) of patients achieving HbA1c<7.0% without GI adverse events. (NCT02243176)
Timeframe: Whole study duration

Interventionpercentage of participants (Number)
Saxagliptin37.0
Acarbose28.8

[back to top]

Proportion (%) of Patients With Any GI Adverse Events

Secondary Objective: Assessment of any gastrointestinal adverse events of saxagliptin versus acarbose. by measure proportion (%) of patients with any gastrointestinal adverse events. (NCT02243176)
Timeframe: 24 weeks

,
Interventionpercentage of participants (Number)
NOYES
Acarbose75.324.7
Saxagliptin94.55.5

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG)

Secondary objective: Effects of saxagliptin versus acarbose on the additional parameters, by measure change from baseline in fasting plasma glucose, 2h postprandial glucose, β-cell function, body weight at week 24 (NCT02243176)
Timeframe: From baseline to 24 week

Interventionmmol/l (Least Squares Mean)
Saxagliptin-0.99
Acarbose-1.01

[back to top]

Change From Baseline in Body Weight

Secondary objective: Effects of saxagliptin versus acarbose on the additional parameters, by measure change from baseline in fasting plasma glucose, 2h postprandial glucose, β-cell function, body weight at week 24 (NCT02243176)
Timeframe: From baseline to 24 week

Interventionkg (Least Squares Mean)
Saxagliptin-1.36
Acarbose-2.05

[back to top]

Change in Microbiome

Changes in bacterial community measurement through DNA extraction from stool samples. Change is measured using operational taxonomic units (OTU). An OTU is the group of organisms being studied through DNA to cluster sequences of microbiomes according to their similarity to one another (the similarity threshold is set to 97%). This outcome measures change in the number of OTUs from baseline to 12 weeks. (NCT02865499)
Timeframe: Baseline; 8 weeks and 12 weeks

InterventionOperational Taxonomic Unit (OTU) (Number)
Baseline Measurement8 Week Measurement12 Week Measurment
Acarbose000

[back to top]